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ABSTRACT 
The design of a solid phase peptide synthesis linker, which on cleavage with 
trifluoroacetic acid leaves the peptide C-terminus with a hydroxy ester functionality, 
is described herein. 
The enhanced rate of hydrolysis of hydroxy esters and carbamates under basic 
conditions has been investigated with a view to utilising this effect in the orthogonal 
protection of amino acid side chains during the syntheses of large peptides. The 
development of protecting groups for both acid and amine side chains has been 
investigated in order that the syntheses of proteins via chemical fragment coupling 
can proceed with a high degree of fidelity. The base hydrolysis of various esters and 
carbamates has been studied, as has the stability of these compounds to acidic 
conditions. The syntheses of a number of protecting group candidates based on 
tris(hydroxymethyl) derivatives has been undertaken and conditions for their removal 
optimised. The syntheses of various test compounds and small peptides utilising 
these types of protecting groups has been completed. The synthesis, purification and 
deprotection of a 32 residue peptide, with one lysine protected as the 
tris(hydroxymethyl)nitromethyl carbamate is also reported. 
The synthesis of a section of the CD4 binding region of the HIV coat protein Gp 120 
has been investigated. Various methods of cysteine protection have been studied and 
the difficulties associated with solubility and protecting group removal highlighted. 
ABBREVIATIONS 
a.a amino acid 
A.A.A amino acid analysis 
ABI applied biosystems 
Acm acetamidomethyl 
AcOH acetic acid 
AIDS aquired immunodeficiency syndrome 
ARC AIDS related complex 
b broad 
Boc tert-butoxycarbonyl 





DCC N,N' -dicyclohexylcarbodiimide 
DCM dichloromethane 
DIC NN'-diisopropylcarbodiimide 





DNA deoxyribonucleic acid 
DTNB 5,5 '-dithiobis(2-nitrobenzoic acid) 
DTT dithiolthreitol 
EDT ethane- 1 ,2-dithiol 
FAB fast atom bombardment 
Fmoc 9-fluorenylmethyloxycarbonyl 
Gdm.Cl guanidinium hydrochloride 
HIV human immunodeficiency virus 
HOW 1 -hydroxybenzotriazole 
HOCt ethyl 1-hydroxy-1H-1 ,2,3-triazole-4-carboxylate 
HPLC high performance liquid chromatography 
HR high resolution 
IR infra red 





Mpt melting point 
MS mass spectrometry 
NMR nuclear magnetic resonance 





PGC porous graphitised carbon 
Pmc 2,2,5,7,8-pentamethylchroman-6-sulphOnyl 
PyBOP benzotriazole- 1 -yl-oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate 
Rp reverse phase 
Rt retention time 
S singlet 
SPPS Solid Phase Peptide Synthesis 




Tbfmoc 1 7-tetrabenzo[a, c,g, i]fluorenylmethoxycarbonyl 
TBTU 2-(1 H-benzotriazole-1-yl)-1,1,3,3- 
tetramethyluroniumtetrafluoroborate 
TEA triethylamine 
TFA trifluoroacetic acid 
TFE 2,2,2-trifluoroethanol 
TFMSA trifluoromethanesulphonic acid 
t.l.c thin layer chromatography 
TMSBr trimethyibromosilane 
Tme tris(hydroxymethyl)ethane derived protecting group 






Amino Acid 3 Letter Code 1 Letter Code 
Alanine Ala A 
Arginine Arg R 
Aspartic Acid Asp D 
Asparagine Asn N 
Cysteine Cys C 
Glutamic Acid Glu E 
Glutamine Gin Q 
Glycine Gly G 
Histidine His H 
Isoleucine lie I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenyialanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Vaiine Val V 
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CHAPTER 1 : INTRODUCTION 
1.1 Introduction 
Solid phase synthesis owes its origins to a paper published in 1963 by Merrifield'. In 
this seminal paper Merrifield described a method of synthesising a polypeptide by 
attaching the growing chain to a solid support. Previous to this work the synthesis of 
peptides had been carried out in solution and had required considerable skill and 
effort. The isolation and purification of intermediates at each step of the synthesis 
was difficult and time consuming. The Merrifield approach eliminated the need for 
these time consuming isolations and enabled vast excesses of reagents to be used 
which allowed equilibrium constants to be forced in one direction. The field of solid 
phase synthesis has grown imeasureable in the subsequent thirty years firstly in 
peptides, then DNA and now today in what is probable the 'hottest" area of chemical 
research, combinatorial libaries. 
The application of solid phase techniques to peptide synthesis has been highly 
refined and automated synthesisers are now capable of producing 100 residue 
peptides almost routinely. The purification and folding of such molecules is however 
less routine and can still present problems to even the most experienced peptide 
chemist. As time progressess and ever more ingenious strategies are developed to 
overcome these problems the chemical synthesis of large proteins is likely to make a 
an even larger impact on the fields of biological and medical research than it does 
today. 
1.2 The Merrifield -Boc Strategy 
The basic principles of the Merrifield approach are shown in figure 1.1 which shows 
the methodology he used to synthesis bradykinine 2. Merrifield had originally used 
the benzyloxycarbonyl (Z) 1 group to protect the N" but soon replaced this with the 
more acid labile t-butoxycarbonyl (Boc) 2 group, figure 1.2. 
- 	CICH2__Ij .__ (POLYSTYRENE) 
BocNfl 	CO2 CS 
I) Attachment of first amino 
acid as Cs salt 
BocNRCHR02 - CH2__r-__(POLYSTYRENE) 
ii) Boc removal with mild 
acid ie TFA/DCM 
	
CF3C0NH3tHR 1P02 	 "H- (POLYSTYRENE) 
I iii) Neutralization followed by 
DCC mediated coupling of 
+ 	Hoc protected amino acid 
B0CNHCNR2CO2NHCHRP02 - CH2___K9___(POLYSTYRENE) 
iv) Repetition of u-iii as 
required to extend 
4' 	peptide chain 
BocNHCHRnCO2-....... NHCI1R02— CH 2__9__ (POLYSTYRENE) 
V) Cleavage of peptide 
from resin with strong 
acid i.e. HF 











In this approach, polystyrene which has been crosslinked by incorporating 1-2% 
divinylbenzene into the polymerisation process is used as the support. The 
polystyrene is functionalized by chioromethylation, and the first amino acid 
incorporated by nucleophilic displacement. The Boc group is then removed as 
indicated and the TFA salt neutralised. Subsequent amino acids are incorporated 
using the coupleing agent N,N-dicyclohexylcarbodiimide (DCC). By repeating these 
steps peptides of the desired length can be manufactured before final cleavage using 
strong acid. During the assembly stage all the side chain functional groups are 
protected using semi-permanent protecting groups which are stable to the mild acid 
conditions which are used to cleave the Na  Boc protecting group. At the end of each 
step the insoluble polymer is extensively washed to remove excess reagents and 
reaction by-products. 
The Merrifield approach, which has changed little over the years has been used with 
great success for the fully automated synthesis of peptides and there are numerous 
reviews  on its use. 
The main problems encountered relate to 1) non-quantitative reactions; 2) 
incomplete orthogonality between the temporary and permanent protecting groups 
and peptide polymer link; 3) side reactions particularly at the final complete 
deprotection stage using the strong acid 
1.3 Fmoc strategy: An overview 
The development of an alternative to the Boc methodology grew out of the above 
mentioned problems, particularly the losses associated with cleavage of the peptide 
polymer link by repetitive exposure to TFA. The undesirability of working with HF 
also added to the demand for alternative methods. 
The Fmoc group 3 developed by Carpino and Han 4 and utilized for peptide synthesis 
by Atherton5 ' 6  offers several advantages over Boc as an N" protecting group. The 
strategy developed around the Fmoc group offers complete orthogonality between 
side chain and Na  protection and avoids the need to use strong acid during the final 
cleavage from the support. Figure 1.3 shows the basic Fmoc strategy 
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i) Attachment of first amino acid 
4 	to the support normally via the symmetrical anhydride using 
DICIDMAP 
O---LINKER---POLYSTYRENE 
I ii) Removal of the Fmoc group 
4, 	using piperidine 
Repeation 	 I 
of these steps A ,oLINKERPOLYSTY1' 
increases the 	 NH2' r peptide chain length 	 o 
iii) Attachment of the next amino 
acid in the sequence, various 
4 	methods available but tradition - 	 by DIC symmetrical anhydride 
0 R 
- / 	
ONt1 *JN,,O --- LINKER --- POLYSTYRENE 
iv) Removal of Fmoc using 
piperidine followed by 
V 	cleavage from the support 
and removal of side chain 
0 	RI 	





The solid support used in standard Fmoc SPPS is a cross linked polystyrene which 
has been flinctionalised with an acid sensitive linker. The first amino acid is attached 
to this as the Fmoc protected derivative. There are various methods of attachment 
although the most common is through the formation of a symmetrical anhydride via 
reaction with DIC in situ. This is followed by displacement by the resin hydroxyl 
catalyse by DMAP. The N' protecting Fmoc group is then removed with base, 
almost always piperidine, to leave a carbamate salt which breaks down to leave the 
free amine. The fluorescent properties of the Fmoc group can be utilise to follow the 
efficency of synthesis since the adduct 4 figure 1.4, formed by piperidine 
deprotection has a distinct absorbance at 302nm. As the resin is washed after each 
step in the synthetic cycle the washings from the Fmoc deprotection steps can be 
passed through a UV monitior to provide a quantitative assessment of the degree to 
which coupling has occurred 7. This is useful in assessing when and where there are 














Amino acids are coupled to the growing chain as Fmoc protected derivatives, there 
are various methods of activating the amino acids and these will be discussed later. 
The cycles of deprotection and coupling are repeated until the last amino acid has 
been added the peptide is then cleaved from the resin and the side chain protecting 
groups removed in one step using TFA. The limited number of synthetic steps and 
the capacity to monitor the efficiency of synthesis has enable Fmoc SPPS to become 
highly automated. 
1.4 Fmuc strategy: The Details 
1.4.1 Resins 
For a resin to be suitable for the synthesis of the growing peptide chain it must 
possess several important characteristics. Firstly, it must have a functionality which 
allows for the attachment of a linker in order to couple amino acids. Secondly, the 
resin must be robust enough to withstand the chemical and mechanical 
transformations which it must under go in the course of a synthesis. Thirdly, the 
resin must swell in a suitable solvent in order for reagents to gain access to reaction 
sites. These properties are associated with polystyrene resins with approximately 1% 
crosslinking with divinylbenzene. The crosslinking provides stability but inhibits 
swelling, 1% has been found to be the approximate optimum in trade off between 
these characteristics. This resin is used worldwide in the synthesis of peptides using 
both the Boc and Fmoc methodologies and has proved highly successful. The main 
draw back of resins of this type however is that they are not greatly solvated by the 
solvents which swell them best. This can lead to aggregation and reduced 
availability of reactive groups. A more hydrophilic support such as the polyamide 
resins used by Atherton & Sheppard 8  should aid solvation of the growing peptide 
chain and in so doing aid diffusion of reagents and lead to increased coupling yields 
and a purer product. The disadvantages of polyamide resins are their limited 
capacity to withstand the continuous flow conditions of modem automated synthesis. 
This can however be overcome by chemically binding them to an inorganic support 













Sheppard's Pepsyn Resin 
Figure 1.5 Resins 
1.4.2 Linkers 
The Fmoc strategy enables the cleavage of the peptide from the resin to be 
undertaken using a much milder acid than is possible for Boc synthesis. This has led 
to the development of convenient acid labile linkers. The Wang  resin 5, which is 
still popular today, was first utilized for peptide synthesis by Chang and 
Meienhofer 1° 
H 






OCH2—j — POLYMER 
OH 
Peptido 
Figure 1.6 showing Wang resin linker and TFA cleavage 
There has been considerable effort devoted to the development of novel linkers 
which, on cleavage, leave the C-terminal amino acid with a functionality other than 
peptide acid. 







CH3 O 	 0-"--POLYMER 
 
Figure 1. 7 examples ofpeptide amide resins 
The need to produce protected fragments has led to the development of very acid 
labile linkers such as the Rink resin 
14  8 which can be cleaved while leaving the side 
chain protecting groups intact. Problems can however occur with the use of these 
types of linker as cleavage can occur with some of the more acidic coupling agents. 
Other linkers do exist which can be cleaved by mild chemical means, such as those 
cleaved by fluoride ions 9 . And it seems likely that, as the need for protected 
fragments grows, ever more ingenious linkers are likely to be developed. 
Linkers can also be designed which inhibit racemisation and side reactions associated 
with certain C-terminal amino acids. The 2-chlorotritylchloride 16  10 linker is for 
instance particularly useful for peptides containing His or Cys as C-terminal residues 






Super acid labile Rink resin 
HOCHcf CHCH2CONH POLYMER 
SCH3)3 	
(9) 
Fluoride Cleavable Linker 
YMER 
2-Chlorotritylchloride Linker Cleaved by acetic acid 
Figure]. 8 
1.4.3 Amide bond formation 
The solid phase synthesis of peptides involves the repetitive formation of an amide 
bond. As this reaction is performed over and over again without purification the 
yield must be as near as possible to 100%. In order to achieve this many agents have 
been developed which activate the carbonyl of the incoming amino acid to attack by 
the NH2  of the growing peptide chain. The attachment of a leaving group to the acyl 
carbon of the carboxy component is necessary because ordinary carboxylic acids 
simple form salts with amines at ambient temperatures. 
12 
__C9C 
R1CO2H 	• R1- C-X 




Figure 1.9 Mechanism ofAmide Bondformation 
In general the better the leaving group X the more efficient the coupling will be. 
1.4.3.1 Carbodiimides 
Carbodiimides have been the single most important reagents for activating carboxy 
groups ever since there use was first reported by Sheehan and Hess in 195516. 
Carbodiimides may be used in direct coupling through an 0-acylisourea 11 or, more 
commonly through an active ester 12 or symmetrical anhydride 13. The latter 
strategy helps alleviate serious side reactions such as racemisation, carboxamide 
dehydration of asparagine/glutamine and the formation of N-acylureas. The two 
most commonly used carbodiimides are dicyclohexylcarbodiimide (DCC) 14 and 
diisopropylcarbodiimidc (DIC) 15, the latter finding favour in automated synthesisers 
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_< 
N,N-diisopropylurea by-product (16) 
Figure 1.10 
14 
1.4.3.2 Symmetrical anhydrides 
The formation of symmetrical anhydrides is relatively straight forward and these 
compounds can be isolated as crystalline solids, however it is more normal to form 
them insitu during synthesis. The use of symmetrical anhydrides has become 
widespread and generally speaking they provide excellent activation and 
unambiguous arninolysis. The drawback associated with their use is that they are 
wasteful in that one complete equivalent is discarded in every coupling. This is 
economically unsatisfactory. The chemical problems associated with them are that 
certain amino acids give serious side reactions. Particularly asparagine and 
glutamine which dehydrate with carbodiimides and histidine which can racemise 
1.4.3.3 Active esters 
The aforementioned problems, and the need for highly efficient couplings has led to 
the development of a number of active esters which again can be pre-formed or 
synthesised in situ using a carbodiimide reagent. As they are at a low level of 
activation (compared to 0-acylisoureas and symmetrical anhydrides) there is less 
chance of side reactions including racemisation occurring. Contrary to the situation 
of ester hydrolysis which will be looked at in detail later, the rate determining step in 
aminolysis of esters is collapse of the tetrahedral adduct not its formation. The most 
important consideration for an activating ester therefore is the leaving ability of the 
ester group. Figure 1.8 shows a number of alcohol components which are all 
















Some examples of the alcohol components of active esters 
Figure 1.11 
17) p nitrophenol 17  ;  18) pentaflurophenol 
18 ; 19) 3 ,4-dihydro-3-hydroxy-4-oxo- 1,2,3-
benzotriazine' 9 ' 20 ; 20) hydroxybenzotriazole' 9 ; 21) 1 -hydroxy-4-ethoxycarbonyl 
1,2,3-triazole2 ' 
1.4.3.4 Other coupling reagents 
Until recently the carbodiimides were relatively unchallenged for peptide work and 
in combination with active ester and symmetrical anhydride derivatives accounted 
for the vast majority of peptides synthesised. With the development of phosphonium 
related compounds such as Castro's 22 benzotriazolyloxy-tris-
(dimethylamino)phosphonium hexaflurophosphate, (BOP) 22 reagent this is begining 
















Figure 1.12 use of BOP reagent 
The main advantages of BOP-like compounds is that they require no preactivation 
the coupling reagent is simply mixed together with the resin bound amino functional 
group, the N" protected amino acid and some tertiary base to ensure the acid is in the 
anionic form. This leads to shorter coupling times and increases the speed of peptide 
synthesis. When one considers that the limiting step in many drug development 
programs is not the screening of candidates but their availability anything which 
speeds up synthesis is looked upon favourably. The main disadvantage of the BOP 
reagent is that the co-product generated by its use is hexamethylphosphoramide a 
highly toxic substance. This has led to the development by Castro 
23  of the related 
PyBop reagent 23 (figure 1.13) 
17 
c NH_Pt__.013 F6 
(23) 
Figure 1.13 
Recent work by Carpino24 ' 25  suggests that by replacing the 1 -hydroxybenzoltriazole 
portion of the BOP and Py BOP reagents with the aza analogue 24 increases in 




Am analogue of I -hydroxybenzotriazole 
Figure 1.14 
It is thought that neighbouring group effects may be important in increasing the 
reactivity of these compounds. 
Another class of direct coupling agent beginning to grow in popularity are the 
uroniumsalts such as 2-(1 -H-benzotriazole-1 -yl)- 1,1,3,3-
tetramethylisouroniumtetrafluoroborate (TBTU) 26 25. These compounds show 







One problem associated with these new reagents as opposed to the carbodiimides is 
there relative cost, TBTU, BOP and Py-BOP being far more expensive than the 
carbodiimide. 
18 
1.4.4. Side chain protecting groups 
In the Fmoc strategy, as aforementioned the N' is protected by the base labile Fmoc 
group and the side chains by acid-labile groups. The following table summarises the 
common side chain protecting groups used. 
Table 1.1 
The mechanisms and principles of alcohol and acid protecting group strategy is fairly 
straightforward. Complications however occur with certain other residues which 
can't be protected in the normal manner. 
Ta 
1.4.4.1 Arginine 
The guanidino side chain of arginine is highly basic and easily acylated during SPPS 
if not protected. Protection of the co—nitrogen normally suffices and attempts have 
been made to protect it as the nitro, urethane, trityl and aryl sulphonyl 28 . The nitro is 
normally removed by H21Pd 
29  although it is prone to a number of side reactions 
during acylation and cleavage 30. Urethane protection via the Boc 3 ' and bis-
adamantyl-oxycarboflYl (Adoc)2 32 groupshas been attempted. This has proved 
unsuccessful as both side chain protecting groups are susceptible to acylation by 
Fmoc-Phe symmetrical anhydride and can subsequently be converted to omithine by 
piperidine27 . The trityl residues of arginine are not soluble in DMF/DCM 33 and 
therefore of little use for SPPS. The sulphonyl derivatives have hence emerged as 
the main arginine protecting groups. The two most commonly used groups are the 4-
methoxy-2,3,6-trimethylbenzenesulphOnyl (Mtr) 34 26 and 2,2,5,7,8-
pentamethylchroman-6-sulphonyl (Pmc) 35 '36  27. The Pmc group has quickly been 
established as the group of choice as it requires significantly less time to cleave in 
TFA. This greatly diminishes the likelihood of alkylation of tryptophan residues by 







CH3O 	 S02—NHCNH- 
CH3 
Pmc (27) Mtr (26) 
Figure 1.16 showing Pmc and Mtr groups 
1.4.4.2 Cysteine 
Cysteine presents a different set of protectioz problems as completed peptides often 
have disulphide bonds between particular cysteine residues. Commonly cysteine is 
FT 
simply protected as the Trt, which is removed during TFA cleavage. This can create 
problems when more than two cysteines are involved in a sequence and a disulphide 
bond is to be formed, as there is no control over disulfide formation. Disulphide 
bonds can hence form randomly and present serious purification and yield problems. 
In order to prevent this and provide a degree of control over disulphide formation a 
series of post-cleavage protecting groups Acm, tBuS, Tacm, tBu have been 
developed which withstand ordinary TFA cleavage. It has been reported that by 
using these groups it is possible to cleave and purify a protected peptide containing 
multiple cysteines and then selectively remove the cysteine protecting groups and 
form disulphide bonds 37 . Although all of the previously mentioned protecting groups 
have been shown to work in the literature none of them is particularly satisfactory. 
The Acm group can be difficult to remove in certain sequences and the tBuS group 
causes solubility problems during purification. The field of cysteine protection is 
still awaiting the arrival of a truly user-friendly, sequence independent, protecting 
group. 
21 














tBuS tributylphosphine, 31 , 1- TFA, AgBF4 
CU3 mercaptoethanol, 44 
S - S CH3 TMSBr45 
( 
FmocNHCHCO2H 
tBu TFMSA,''4 ' mercury TFA, AgBF4ITFA 




• Table 1.2 
*Care must be taken using iodine as it can attack tryptophan residues 
38 this can 
however be mininised. 39 
**Both Met and Trp residues must be protected when using this protocol. 50 
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1.4.5 Side reactions associated with SPPS 
1.4.5.1 Racemisation 
During the synthesis of a peptide there are a number side reactions which can occur. 
One of the main concerns when dealing with optically pure compounds is 
racemisation and a great deal of effort has been put in to keeping this to a 
minimum51 . Due to the conditions used during synthesis, there is, except in the case 
a few special amino acids (a—phenylglycine residues, certain His and Cys 
derivatives), very little racemisation by direct enolisation. The main source of 
racemisation is the tendency of activated acylamino acids and peptides to cyclize 
under the influence of base to give oxazolones 28. The oxazolones formed are 
themselves activated towards the incoming amino acid, but because the rate of 
racemisation via resonance stabilized anions is usually much faster than the rate of 
peptide bond formation, any peptide produced is likely to be highly racemised. 
H 
R, 	
RI.. <Z...R 	Base 
	






Figure 1.17 Racemisation via oxazolone 
Oxazolone formation occurs with most good leaving groups X. Fortunately however 
this is not so easy when the acyl substitution is an alkoxycarbonyl protecting group. 
Further more the alkoxyoxazolones are less easily racemised and more easily 
23 
aminolysed than are the oxazolones. Hence for Z, Boc and Fmoc protected amino 
acids there is normally little danger of racemisation occurring. 
1.4.5.2 Diketopiperazine (DRIP) formation 
The main area of concern with this side reaction is the deprotection of the second 
amino acid in a growing peptide chain. Under certain conditions cyclization can 





A diketopiperazide (29) 
Figure 1.18 Diketopipeazine formation 
Most of the time losses due to DKP 29 formation are minimal. Certain residues such 
as glycine, proline, valine, and isoleucine enhance the tendency to cyclize, as does 
the incorporation of L and D amino acids as the side chains will lie on opposite sides 
of the general plane of the DKP ring and hence make cyclization more favourable. 
Inhibition of cyclization is possible by using t-Butyl protecting groups or in extreme 
cases by loading the second and third amino acids as a dipeptide. Protected and 
24 
activated derivatives of glycyl-proline also cyclise by a similar mechanism to yield 
acy1diketopiperazines 52 . 
1.4.5.3 Aspartimide formation. 
Aspartimide 30, formation is perhaps the most serious side reaction in peptide 
synthesis it can occur by both acid and base catalyzed mechanisms. It is however not 
normally a problem when amino acids with bulky side chains 
53  are C-terminally 
adjacent to the aspartic acid residues. These bulky side chains inhibit attack by the 
lone pair of the nitrogen by steric means, thus limiting aspartimide formation. 
Serious problems can however occur when less hindered systems are present. This is 




Figure 1.15 Aspartimide formation 
Figure 1.15 shows the general mechanism of aspartimide formation, hydrolytic ring 
opening at the -carbonyl regenerates the original peptide (less the side chain ester) 
attack at the ct-carbonyl is however favoured and leads to the P-linked peptide. 
Aspartic acid is normally protected as the t-butyl ester this gives effective protection 
as regards external nucleophiles but is inadequate in halting aspartimide formation 33 . 
Several efforts have been made to synthesise a reliable 3-aspartic acid protecting 
group which will prevent the troublesome Asp-Gly rearrangement. Little success has 
yet been achieved although recent work on adjacent glycine backbone protection has 
proved promising 56. Other current techniques which seem to limit the rearrangement 
include the practice of adding an active ester such as FIOBt or Pfp to the deprotection 
cycle in the Fmoc protocol to act as a buffer 57 . 
25 
1.4.6 Cleavage and scavengers 
Cleavage of the completed peptide from the resin is normally achieved in Fmoc 
chemistry using TFA. The side chain protecting groups are, in the main, also cleaved 
by the TFA. This creates a number of stable cations which can attack electron rich 
sites in the deprotected peptide. The side chains of tryptophan, tyrosine and 
methionine are particularly susceptible in this respect. In order to prevent this, 
additives such as water, thioanisole, anisol, phenol, and 1 ,2-ethanedithiol which 
"scavenge" these reactive cations are added to the cleavage mix. These additives act 
not only by trapping carbocations, but also as nucleophiles in the cleavage step by 
shifting the mechanism of cleavage from SN1 to SN2 in certain less easily cleaved 
protecting groups. 35 Normally, cleavages involving peptides without such sensitive 
amino acids and only requiring the deprotection of t-butyl groups can be achieved 
using 95% TFA!5% water. For other sequences however scavengers are required. 
In an attempt to cut cleavage time several groups have experimented with the use of 
stronger acids than TFA such as TFMSA 58 and TMSBr 	These are promising 
developments and could be particularly useful for the cleavage of large peptides. 
1.5 Large peptide/protein synthesis 
The technology of SPPS ultimately has limitations and it is difficult to foresee the 
stepwise synthesis of peptides containing over 200 residues becoming commonplace. 
The main problem is that structural interactions in the growing peptide chain cause 
the accessibility of the primary amine to be reduced. Coupling efficiency gradually 
drops and a point is eventually reached whereby a synthesis is no longer viable. 
In an effort to over come these intrinsic problems several groups have attempted to 
synthesis large peptides by convergent means. The basic strategy involves 
synthesising small fragments of a larger peptide by traditional SPPS techniques, 
purifying them and then coupling these purified fragments together to form the larger 
peptide. Other than overcoming the problem of reduced coupling efficiency the main 
advantage of this technique is that it is obviously easier to separate a 100 mer from a 
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mixture of two pure 50 mers than from a mixture containing any number of 
truncations. 
There are several ways in which the fragments can be coupled and not all of them 
involve peptide bonds. Work by Kent on the synthesis of HIV- 1 protease has 
utilized a novel thio ester linkage 
60  and the Tam group has reported conjugation 
through a five membered ring 61 . While these are interesting asides it is obviously 
desirable to link fragments through peptide bonds as only then can the structure be 
guaranteed to resemble the natural state. The Kent group have made significant 
progress in this area by linking fragments through a peptide bond formed by the 
reaction of an N terminal cysteine and a C terminal thio ester. The coupling is 
carried out in guanidine solution at pH 7.6; both fragments being unprotected despite 
the presence of other cysteine residues in the sequence. 
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More traditional forms of c'oupling between fragments include coupling via 
enzymatic means by manipulating the equilibrium constants of certain proteolitic 
enzymes 63  and those involving an azide 32 mediated linkage 
14,61,66  first introduced by 




o 	t-butyl nitrite 
- 	Rfl—K (32) 





Figure 1.15 hydrazide/azide peptide method by Honzl & Rudinger method 
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The obvious draw back of these methods is that the side chain amino groups of all 
the lysine units, in both fragments, have to be protected in order to prevent them 
interfering with the fidelity of coupling. This has presented several problems as 
lysine is normally protected by the Boc group, which is of course removed by TFA 
during cleavage from the resin and therefore unsuitable for fragment coupling work. 
What is required therefore, is a lysine protecting group which has a number of 
exacting qualities. 
It must be able to withstand the conditions of SPPS. 
It must be stable to TFA cleavage. 
It must be unaffected by the conditions required for fragment coupling. 
It must be easily removable after fragment coupling. 
It must be relatively cheap and easy to introduce to the lysine side chain. 
It must be as solublising as possible. 
The presence of aromatic groups within post cleavage protecting groups is limited as 
they drastically reduce the solubility of the fragments they protect. Large peptides 
protected in such a manner can be insoluble thus rendering purification or further 
reactions exceedingly difficult. There are a number of protecting groups which have 
28 
been used to protect lysine orthogonally in conjunction with the Fmoc and Boc 
strategies, such as the penicillin acylase cleaved PhAc 68 group 33, the Dde 69 ' 7° 34, 
Alloc7 ' 35 groups, as well as various light sensitive molecules. 
Q 
0 NH Lys CH3
>c =c, 	






Figure 1.16 Orthogonal lysine protecting groups 
There is as yet however no protecting group currently on the market which 
adequately fulfills the aforementioned requirements for the synthesis of large systems 
and subsequently these methods of fragment coupling have been under used. Later 
text will endeavour to describe the discovery, development and testing of a highly 
promising multipurpose lysine protecting group. 
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CHAPTER 2: POST CLEAVAGE PROTECTING GROUPS 
2.1 Evolution of a post cleavage protecting group 
As previously discussed, one of the main areas of current research into protein 
synthesis by chemistry methods is fragment coupling. The concept being that several 
of the limiting factors associated with SPPS can be overcome by coupling together 
two, or more, smaller fragments to make up a protein. As outlined in the 
introduction this can be facilitated by a number of techniques. These can, however 
be subdivided into two main categories. 
Enzymatic fragment condensation. 
Chemical fragment coupling. 
In our initial investigations into fragment coupling we sought to devise a linker 
which, when cleaved from the resin, would leave the peptide with a novel C-terminal 
ester functionality. This novel functionality would, hopefully, give us two options 
for uniting peptide fragments. 
The ester moiety would act as a substrate for enzymatic condensations. 
The ester functionality would be designed in such a way as to give the opportunity 
for chemical coupling via catalysis with a Lewis acid such as boron. 
With these dual aims in mind the structure 36 shown in figure 2.1 was chosen as the 
one most likely to possess the novel functionality required. 
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Figure 2.1 
2.1.1 Linker synthesis 
It was necessary then to synthesis a linker which could easily be attached to a resin, 
would be stable to SPPS using Fmoc methodology, and which would subsequently 
be cleaved under normal (TFA) cleavage conditions to give the structure 36 shown in 
figure 2.1. 
The compound shown in figure 2.2 37 was selected as the molecule most likely to 










Several synthetic routes were attempted before a successful synthesis with 
practicable yields was found. The final route varies slightly, in that the target 

























Dean Stark conditions 
(40) 
Figure 2.3 Linker Synthesis 
This was because isolation of the acid proved to be difficult due to nonselective 
hydrolysis of the two ester flinctionalities present. As a result the linker was loaded 
onto the resin via the pentachlorophenyl active ester rather than using DIC to 
generate the symmetrical anhydride. The yield of this step was> 70% hence this 
approach did not decrease the efficiency of the route. The synthesis of a short test 
peptide Leu-Ile-Phe-Ala-Gly incorporating the linker was undertaken using Fmoc 
SPPS methodology. Unfortunately this initial synthesis failed and analysis of the 
deprotection profile' showed a major drop in dibenzofUlvene-piperidine adduct 4 
absorption after addition of the third residue (section 1.3). This was almost certainly 
due to diketopiperazine 29 formation (section 1.4.5.2). Resynthesis of the test 
peptide AlaAsp-Leu-Ile-Leu-dPhe-Gly 45 in which introduction of the second and 
third amino acids as a dipeptide resulted in a more successful synthesis albeit with a 
low yield. As can be seen from the deprotection profile of this second peptide (figure 
2.5) there is gradual levelling off of the profile as further amino acids are added. 
Whether or not this trend would continue on a long sequence is problematic. The 
reasons for the initial steep fall off even discounting diketopiperizine formation are 
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Figure 2.5 deprotection profile peptide 45 
2.1.2 Chemical fragment coupling 
After successfully synthesising the functionalised peptide a series of attempts were 
made at coupling it through its ester moiety to incoming amino acids. To this end a 
series of reactions were set up whereby the Fmoc protected peptide 45 was added to 
Lewis acid buffers such as H 3803 Aid 32, SnC123 at various pH's. A number of 
amino acids or dipeptides were then added in an attempt to find conditions under 
which a Lewis acid would catalyse fragment coupling. These elusive conditions 
were not found. What was discovered however was that under relatively mild basic 
conditions the diol ester 45 could be cleaved to yield the acid. 
0 
OH 
(45) 	 NO2KOH 
Figure 2.6 
This discovery opened up a number of interesting possibilities. Firstly, as the diol 
ester appeared to be cleaved relatively easily in basic solution but its precursor, the 
protected acetal, was stable to Fmoc SPPS protocols, it was potentially a post-
cleavage protecting group. The necessity of which has been highlighted earlier. 
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Secondly, as a hydroxylic compound its utility as a protecting group could be 
enhanced by solublising the protected peptide. The problem of protecting groups 
causing drastic reductions in the solubility of peptides is well known not least in this 
laboratory4 . The properties of the group also mean that it would be compatible with 
the modified form of the Honzl & Rudinger 5  (section 1.5) azide coupling strategy 
currently used for the fragment condensation of peptides 6 . 
Azide Fragment Coupling Strategy 
normal peptide synthesis 
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Deprotect Fmoc group 
to leave desired Peptide 
Figure 2.7 Modified Azide coupling 
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2.2 Ester hydrolysis 
In order to examine the extent to which the diol functionalised ester could be cleaved 
in basic solution it was necessary to synthesis a model compound which could then 
be used for testing. The compound 51 was chosen as it provided a simple example of 
a carboxylic acid, possessed a fluorescent tag and had a suitable retention time on 





The retention time was important as reactions were followed by HPLC. The 
synthesis of 51 was relatively straightforward and a program of research was 
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Figure 2.9 showing synthetic route to compound 51 
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2.2.1 Cleavage conditions 
Initially a solution of 51 ('-)mg/ml) in acetonitrile was made up. This was then added 
in imi aliquots to epindorphs containing imI of 1% (0.162M) boric acid solution 
which was buffered with a mixture of HCI and Na,CO 3  to give the required pH. The 
Epindorph tubes were allowed to stand and at convenient time intervals 1541 samples 
were withdrawn, diluted to 0.1ml with pure acetonitrile and 20a1 of this solution 
injected then onto a analytical HPLC column. As can be seen from figure 2.10. two 
peaks are evident one of which corresponds to the unreacted ester the other to the 
product Fmoc-glycine. The relative height of each peak is dependent on the degree 
to which hydrolysis has occurred when the sample is injected onto the column. By 
assuming that at time zero the ester peak represents 100% and then calculating the 
proportion of this relative to the growing acid peak, over time a decay curve can be 
plotted. Statistical analysis of which correlated well with pseudo first order rate 
kinetics and therefore gave a dimensions rate constant. A series of reactions were 
carried out in this manner over a pH range from 2-9 the results of which are 
summarised in graph (2.1) and table (2.1). 
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Graph (2. 1) showing rate of reaction at varying p11 
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The rate of reaction was initially compared against the hydrolysis of Fmoc-glycine 
phenyl ester 56 and compound 55.(Table 2.2) 
Compound 51 	8 	2.40 Hours 
Fmoc phenyl ester 8 	23.45 Hours 
56 
Compound 55 	8 	26.10 Hours 
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There were indeed differences in the rates of hydrolysis of the three compounds. The 
diol compound having by far the fastest rate confirming the earlier suspicions 
encountered with the C-terminal peptide derivative 45. 
Examination of table (1) indicates that the rate of hydrolysis for 51 is dependent on 
pH, the half life being inversely proportional to the OH ion concentration. The 
subject compound also appears to be completely stable in strongly acidic conditions 
suggesting that hydrolysis is catalysed by OW ions alone. 
2.2.2 Theory of ester hydrolysis 
There are a number of mechanisms in the literature which explain ester hydrolysis, 
this is unsurprising since hydrolysis of an ester can take place under a number of 
different conditions and is catalysed by both acid and base. A classification of these 
various mechanisms was carried out by Ingold 7 and the naming system he provides 
proves most useful when discussing these types of reaction. The mechanisms are 
classified according to the following criteria: acid or base catalysis, denoted A or B; 
which carbon oxygen bond is cleaved, acyl AC or alkyl AL; molecularity,1 or 2. 
The acid catalysed reactions are reversible, and mechanistically ester formation is 
equivalent to hydrolysis. Base catalysis however forces the equilibrium in the 
direction of hydrolysis by the effectively irreversible ionisation of the carboxylic 
acid. 
These mechanistic abbreviations will be referenced in the later text. 
Of the possible mechanisms for hydrolysis the one which at first glance would appear 
to be most likely for molecule 51 is the BAC2 mechanism shown below. 





This mechanism does not of course account for the increased rate of hydrolysis over 
and above that of the control compounds. The increased lability of 51 must be 
related to its structure. This could manifest itself in a number of ways, through intra-
molecular catalysis by the OH groups, through interaction with the boron from the 
buffer or possibly via some solvent sorting mechanism. A survey of the literature 
showed that the increased rate of hydrolysis of hydroxylic esters as opposed to their 
non-hydroxylic analogues has been investigated before, indeed there is a 
considerable body of work on the subject which appears to have been in particular 
vogue in the early 1970's. The first paper discussing the subject was that by Bartlett 
and Green' °  who noticed that a hydroxyl group in the 2-position of methyl triptoate 
increased the rate of hydrolysis. While methyl triptoate was hydrolysed by KOH in 
ethylene glycol on heating for one hour at 130 °C , the 2-hydroxy ester 57 was 
saponified in 2 minutes. Further early work included that by Kupchan Slade and 
Young  who examined the rate of base hydrolysis of cholestane-3b,4b,-diol 
monoacetates 58. The neighbouring hydroxyl group was reported to increase the 
rate of ester hydrolysis in these vicinal cyclohexane-diol monoacetates by 8 to 9 
times over that noted in corresponding cyclohexane monoacetates. These 
observations were supported by Bruice and Fife 9  on a series of 2-hydroxycyclopentyl 
carboxylates 59 and support the conclusion that neighbouring hydroxyl groups 
increase the rate of hydrolysis. 
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The data in table 1 is roughly in line with these later findings so it would appear that 
compound 51 exhibits an example of what has become known as known as the 
Henbest-Kupchafl 89" 1  effect. A situation whereby the neighbouring OH group is not 
acting in a nucleophilic manner, in which case a lactone would be formed, rather it 
acts in solvating the transition state for nucleophilic attack by an external hydroxyl 
ion on the ester carbonyl ie. a modified form of the BAC2 mechaism. 
Later work by Capon 12 suggested that in some instances solvent sorting may 
also have an important role to play, however for most cases the above theory is 
generally accepted. In addition to anchimeric assistance by the OH group there is 
also literature supporting a catalytic 	 by the borate which will be 
discussed later. 
What appeared to have been a reasonably serindepidous discovery, i.e that 
diol esters are cleaved relatively quickly in basic acetonitrile/water mixtures proved 
to be an example of a well known effect. What does not appear to have been realized 
however is the potential of these compounds to act as protecting groups, similarly 
there appears to have been very little effort made to optimise the conditions for 
removal of these hydroxy esters. A program of research was therefore undertaken to 
try and optimise these conditions and adapt them for use in peptide chemistry. 
2.3 Tris(hydroxymethyl)nitromethafle (41) derivatives as protecting groups in 
peptide chemistry 
2.3.1 Deprotection optimisation 
In any attempt to increase the rate of a reaction the first variables to be altered are 
generally temperature and mixing. As peptides are natural products it was desirable 
to limit temperature rises to 37 °C as this is the natural operating temperature of the 
body. In the case of mixing it was thought that sonication would be the best, and 
certainly the most reproducible method of agitation. From the initial studies it was 
also known that increased pH would increase the rate of hydrolysis. It is however 
desirable, when dealing with proteins, to minimise their exposure to high pH as this 
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can cause unwanted reactions with the side chains of certain amino acids and also 
begin hydrolysis of the amide backbone. With these limits in mind the role of the co-
solvent used with the aqueous buffer in the hydrolysis reaction was investigated. In 
these experiments a lmg/ml solution of 51 was made up in various solvents 0.4m1 
aliquots were removed and placed in epindorph tubes containing 0.2ml of borate 
buffer {0.2M sodium borate, with 0.2M boric acid proportionately mixed to give the 
required pH). This buffer replaced the 1%(0. 162M) boric acid buffer previously used 
purely due to ease of preparation and in did not appear to effect the rate of reaction. 
The reaction vessels were then floated in a sonic bath at room temperature. At 
convenient time intervals aliquots were removed and injected on to an analytical 
HPLC column whereupon it was discovered fairly quickly that by switching from 
acetonitrile to DMSO as the chosen co-solvent a large increase in the rate of reaction 
could be achieved (see table 2.3 ). Again a rationale for explaining this was to be 
found in the literature 
16,17,18,19,20 
	
Compound 51 1 Ethanol 	18.0 1 4.001-lours 
8.0 I 2.401-lours I borax 
51 I DMSO 	18.0 110 minutes I borax 
2.3 
2.3.2 Aprotic dipolar solvents 
DMSO is a dipolar aprotic solvent similarly so are DMF, acetonitrile and, to a lesser 
extent, acetone. These solvents in spite of being highly polar lack the ability to 
donate hydrogen to form hydrogen bonds and this is important for a number of 
reasons. Firstly in any reaction which involves nucleophilic anions in aqueous 
solution there exists around each anion a solvent shell of water molecules which 
inhibits the reactivity of the ion. Dipolar aprotic solvents lacking the ability to form 
hydrogen bonds do not solvate anions and hence the effective reactivity of the anions 
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is increased. Provided there is sufficient mole fraction of dipolar aprotic solvent 
within an aqueous mix the anions will exist effectively as naked species, since the 
dipolar aprotic solvent will engage the hydrogen bond donating water molecules as 
dipolar aprotic solvents are strong hydrogen bond acceptors. This capacity to 
desolvate anions influences the rate increases in many nucleophilic substitution 
reactions. There is however a secondary effect which takes place when a 
neighbouring group is capable of anchimeric assistance 12 . In this scenario an 
internally hydrogen bonded transition state structure as in figure (2.13) is more 
highly favoured by aprotic as opposed to protic solvents. 
- 	Stablised transition state 
06 
L proposed by Bruice & Fife 
6-6H 
Figure 2.13 
This is due to the charge distribution being more similar to an SN2 transition state as 
opposed to that of normal esters in which there is a localisation of negative charge on 
the carbonyl oxygen 9 . 
Y 
 YCX 	 + 
SN2  Mechanism 
Figure 2.14 
Dipolar aprotic solvents are better able to solvate these charge dissipated transition 
states and therefore lower the activation energy necessary to reach them. This in turn 
increases the rate of reaction. 
As an aside it is interesting to note that the rate of removal of the Fmoc group, 
compared with the Trim group, is far faster in protic solvents than in dipolar aprotic 
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solvents as is illustrated in the below HPLC trace (Fig 2.15) which shows compound 









0 	 20 
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Figure 2.15 
This lends extra evidence to the theory that some special form of intramolecular 







Figure 2.16 Showing how Bruice & Fife model 
might be applied to compound 51 
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2.3.3 Kinetics 
In an effort to find out how the rate of reaction in DMSO would be effected by 
temperature a series of reactions were carried out in which the rate of hydrolysis was 
monitored at three different temperatures. 
2.3.3.1 Method 
A stock solution of compound 51 was made up (1mg/mi in DMSO), again 0.4m1 
aliquots of this were taken and placed in epindorph tubes which were then placed in 
the cold room and allowed to freeze. This procedure was necessary because on 
adding buffer to DMSO there is a large enthalpy of mixing of the two solvents and 
this raises the temperature quite considerably in the confines of an epindorf tube. 
Consequently without some effort being made to negate this temperature rise any 
kinetic data relating to temperature would be highly inaccurate. At the beginning of 
each kinetic run 0.2m1 of buffer (pH 8.5 borate) was added to the top of a frozen 
epindorph tube and the epindorph tube floated in a sonic bath. At the designated 
time the reaction was quenched by injection of a further 0.2ml of acetic acid. The 
quenching of the reaction allowed several epindorph tubes to be sonicated at the 
same time and therefore under the same conditions. These could then be analysed 
separately and the results averaged. The decay curves were calculated as previously 
described and are summarised in graph (2.2). 
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Graph 2.2 
As can be seen the rate of reaction is increased by temperature as would be expected. 
The rate of cleavage is also exceptionally fast and hence the diol ester should prove 
an excellent protecting group. 
2.3.4 Buffer effects. 
As previously mentioned there is some evidence to suggest that under certain 
situations borate buffers can act in a catalytic manner. Work by Capon  suggests this 





+ OH (H2O) 
Hydrolytic products -  
oQ 
Figure 2.17 after Capon 14 
In order to examine this phenomena a series of kinetic experiments were under taken 
useing borate, phosphate and Tris, [tris(hydroxymethyl)aminomethafle] buffers. 
Unfortunately the reactions involving Tris were difficult to follow due to the 
appearance of an unknown product, possibly the result of a reaction between the 
buffer and cleaved Fmoc. The rate of reaction with Tris where it could be assessed, 
was however much slower than for either borate or phosphate buffers cleavage taking 
over 20 hours at pH 8 in DMSO at room temperature. 
The experiments involving phosphate and borate were carried out using exactly the 
same method as described previously and in the experimental section. The buffers 
were however at pH 8 rather than 8.5 in order to make the reactions slower and 
53 
illustrate any rate differences more dramatically. As can be seen from graph (2.3) 
there are indeed differences in the rate of reaction in the two buffers. 
Comparison of hydrolysis of compound 51 in phosphate and borate 
buffers at 10 °C and pH8 
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Graph2. 3 
It would appear that borate does have some catalytic effect under the conditions 
examined and that phosphate may also to a lesser extent act in a similar way. 
Whether this is through a complex with the hydroxyl groups or through some 
interaction with the solvent is difficult say. The results do however support the 
evidence of the previously cited literature and could be due to existence of 
intermediates similar to those shown in figure 2.18 
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Figure 2.18 Showing how borate might stabilise the transition state 
Intermediates of this type were of course implicit in the original plan (figure 2.1); 
although for completely different reasons. 
Whichever mechanism is operating, and it is far from certain at this stage, the 
removal of the diol has been achieved in mildly basic solution and in good time. 
Hence we can be practically, if not intellectually satisfied. A survey of possible 
mechanisms will be discussed later. 
2.3.5 Other Systems 
Further work was carried out to check the validity of the diol on other amino acids, 
whether or not it was stable to piperidinefDMF and if it could be applied to amino 
protection. 
2.3.5.1 Stability 
At this juncture we have a protecting group which as an acetal appears to be stable to 
the basic deprotection conditions of SPPS. However when the acetal is cleaved in 
aqueous TFA to yield a diol we have a protecting group which can easily be removed 
to give the acid function. Although the synthesis of peptide 44 has been achieved 
under SPPS conditions, there was, as reported, a low yield. In order to check that 
this was not due to instability of the proposed acetal protecting group to 
DMF/piperidine, the Z-phenylalanine derivative (61) was synthesised and a 1mg 
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sample subsequently dissolved in lml of DMF/piperidine (4:1). Aliquots were taken 
at convenient time intervals and injected on to an analytical HPLC column. After 
four hours there was still no change in the HPLC trace and the acetal was thus 









Figure 2.19 compounds 61 & 62 
It was also necessary to find out if the diol itself could be cleaved by DMF/ 
piperidine as it was important to know whether or not it would be stable to the 
conditions used to remove the Fmoc and Thfmoc groups. In order to assess this the 
Z-phenylalanine derivative 62 was synthesised and tested briefly with borate/DMSO, 
to confirm that the diol group was removed with similar ease to that of the Fmoc-
glycine derivative suggesting broad-based applicability for acid protection. 
The stability of 62 was then tested against DMF/piperidine (4:1). Figure 2.20 shows 
an HPLC trace of 62 after 70 minutes in the DMF piperidine mix. 
The half life for removal of the diol proved on average to be approximately 90 
minutes which is much slower than for either Fmoc or Tbfmoc. An investigation as 
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to whether the piperidide or the acid was formed during the reaction was carried out 
to try and shed some light on the mechanism. 
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Figure 2.21 showing the two possible mechanism 
The Z-phenylalanine piperidide 63 was synthesised and examined under HPLC in 
comparison with 62 and Z-Pheny!alanine-OH. 
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Figure 2.22 shows the HPLC traces of the three pure compounds. Figure 2.23 shun's 
the trace of compound 63 & Z-Phe-OH. While figure 2.24 shows the HPLC 
of an 
injection of all three. 
As can be seen from the HPLC traces, the acid, rather than the later eluting 
piperidide is formed. This suggests that it is OH' ions produced by the basic 
piperidine reacting with water in the DMF, rather than the piperidine itself which 
cleaves the diol group. This leaves open the possibility of selective cleavage of 
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Tbfmoc in the presence of the diol ester but would require very dry solvents which 
may be difficult to reproduce. Whether this is feasible or not would require further 
research. 
2.4 Other tris(hydroxymethyl)ester derivatives 
So far the only compounds actually tested have been derivatives of Trim 41 thus in 
order to see if other compounds of this type have similar properties the methyl 
derivative 64 was synthesised from the 1,1,1 -tris-(hydroxymethyl)ethane (True) 64a 
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Figure 2.25 showing compound 64 
The synthesis was analogous to that used for 51 and presented no problems. The 
compound 64 was tested under the same optimised conditions as for 51 and appeared 
to cleave faster than 51, quantification of these results proved difficult because of the 
speed of reaction. As can be seen from figure 2.27, 2.28 the rate of hydrolysis of 64 
is dramatically quicker than for 51. In addition to this figure 2.29 shows that 
compound 64 can be cleaved by deionised water if DMSO is present. 
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Figures 2.27 (left 64) and 2.28 (right 51); Comparison of Hydrolysis of both 
compounds in DMSO/ Borate 2:1 pH8.5 after Smins. 
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Figure 2.29 Compound 64 after 25 mins in DMSOfDeionised Water 2:1 
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It was later found that 64 was unstable when exposed to the atmosphere slowly 
breaking down to form Fmoc-glycine (half life approximately one month). Since 51 
appears to be completely stable and has been stored as both as a gum and in solution 
for over a year this is a curious result. The capacity of both compounds to form 
gums on exposure to air, presumably by absorbing water, may be important. 
Compound 64 being less stable is perhaps hydrolysed by the absorbed water. This 
hypothesis is supported by the fact that compound 64 has good stability when stored 
in water free solvents such as DCM. It is difficult to make inferences as to the role of 
the nitro and methyl groups in these compounds because of the uncertainty in 
information gained from studies on the methyl derivative. 
2.5 Lysine protection 
As previously discussed (section 1.5) in order to perform reliable fragment coupling, 
be it by chemical or enzymatic means, it is necessary to protect amine as well as acid 
groups. To this end, and after the success of the Turn group in protection of acid 
functions, attempts were made to assess its potential as an amine protector. The 
protection being in the form of the carbamate derivative of Trim. 
RODCOXQ 
(65) 
Figure 2.30 Protection of an Amine as a Carbamate 
It was necessary therefore to synthesis a test compound which could be used in a 
similar manner to 51 for optimising the conditions necessary for deprotection. 
It was perceived that removal of an amine protecting group of the above type would 
be more difficult than in the protected acid situation. This is because the lone pair of 
electrons on the nitrogen are capable of entering into resonance with the carbonyl 
double bond and therefore stabilizing the compound to hydrolysis. Due to the 
increased stability of urethanes towards hydrolysis it was decided to synthesise a 
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model compound without the Fmoc moiety as this could be deprotected if the 
conditions ultimately used had to involve a high pH. As it was still desirable to have 
a fluorescent tag and suitable retention time on HPLC the compound 66 was chosen 
as the target test molecule. 
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Figure 2.31 Compound 66 
The synthesis of this compound is relatively straight forward the only problem 
occurring in the activation of the carbamate for attack by the amine. This was 
initially attempted by trying to form the chloroformate of compound 53 (figure 2.9, 
section 2.2) but this proved a difficult compound to isolate due to its instability. It 
was hence decided to convert the unstable chioroformate into an activated carbonate 
and thus avoid the need to isolate the unstable intermediate. Various methods of 
activating the alcohol were tried and some success was achieved with the p-
nitrophenol mixed carbonate which was formed by reaction of 53 with triphosgene 
and p-nitrophenol. 
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Figure 2.32 Synthesis of Compound 67 
The best over all yields were however achieved with use of the pentaflurophenyl 
derivative 69 which had the added advantage of being easy to crystallise. It was 
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Figure 2.33 
Once 66 had been synthesised a number of reactions were carried out to assess its 
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Figure 2.34 Synthesis of compound 66 
rri 
Before any investigation into the conditions for hydrolysis of 66 was undertaken the 
synthetic precursor of 66, namely 73 was tested for its stability to piperidine/DMF 
and therefore the ability of the protected carbamate to withstand conditions on the 
synthesiser. There was no noticeable change in HPLC profile after 4 hours in 20% 
piperidine/DMF and hence the overall structure was thought to be compatible with 
SPPS. A series of hydrolysis reactions were then carried out on 66 in a number of 
solvents to assess their effect (Table 2.3). 
Table Li 
Broadly speaking the results were very similar to those for 51 the rate of deprotection 
being maximised in DM50/borate. There are however some important differences. 
If the below HPLC traces are examined it can be seen that the hydrolysis of 66 is less 
"clean" than for that of 51 and that the choice of solvent will affect the cleanliness of 
reaction. The more dipolar aprotic in nature, the cleaner the reaction, also the higher 
the pH the cleaner the reaction. 
Hydrolysis of Compound 66 
in DM50/Borate at pH8 
Hydrolysis of Compound 66 
in Acetonitrile /Borate at pH8 
Compound 
Compound 66 
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These additional peaks are obviously intermediates or side products in the hydrolysis 
of 51; exactly what they might be and how they can be removed will be discussed 
later. It is worth noting however that although the rate of reaction is slower using 
Tris buffer it is much cleaner than with borate. 
Minutes 
Figure 2.35(B) showing how buffer affects cleanliness of reaction: rig/it trace pure 
66; Left trace same sample after 7 hours in pH8 D*ISO/Tris. 
2.5.1 Kinetics 
As with compound 51 and using the same method a series of reactions were 
subsequently performed at three different temperatures to provide kinetic data. As 
can be seen from the graph 2.3 the rate of reaction is temperature dependent also the 
reaction becomes cleaner at higher temperature with fewer side products being 
observed. 
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Hydrolysis of compound 66 at three different temperatures in pH 8.5 
Borate buffer/DMSO 
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2.5.2 Protection of lysine in a peptide 
The ability of the carbamate acetal structure to withstand mock SPPS conditions has 
been ascertained, as has the capacity to remove the diol compound formed after 
hydrolysis. All that remained was to test the strategy on a real peptide. In order to 
achieve the broadest possible specification it was decided to attempt to protect lysine 
as the True 64a derivative. As it was thought that this could be more easily 
incorporated into the synthesis of protected glutamic/aspartic acid residues as well as 
lysine. The reason for this is, that although it is by no means the only route, the most 
convenient synthesis of these protected GluJAsp residues involves hydrogenation 
(figure 2.36) and it was thought that the Trim nitro group may be converted to an 
amine during this process. As this would obviously compromise the use of the Tam 
derived molecule as a protecting group the Tme derivative was used for this initial 
synthesis. 
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Figure 2.36 Synthesis of the Tme derivative of Glutamic acid 
0 
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Having decided to protect lysine using the True derivative, and having attached it to 
Fmoc-lysine via the pentaflurophenyl carbonate 78, to give compound 79, all that 












Figure 2.37 Synthesis of Compound 32 
The short peptide Phe-Gly-Lys(Tme)-Ala-Gly-Gly (80) was synthesised on an 
Applied Biosystems 430A synthesiser using the method outlined in the experimental 
section. 
After standard purification, via semi-preparative HPLC, removal of the protecting 
group was attempted with borate buffer at pH8.5 in DMSO; this was however 
unsuccessful. The pH was increased to 10 without effecting deprotection. This was 
a curious result considering the rate of deprotection for the methyl group was faster 
than that of the nitro derivative in the esters previously tested. This was somewhat 
disappointing as the protecting group had failed in its first real test. In order to assess 
whether there was an intrinsic problem associated with removal from peptides, as had 
been experienced with other protecting groups, or whether the methyl group was 
71 
stable to hydrolysis in the carbamate form yet subject to hydrolysis in the ester form, 
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Figure 2.38 Synthesis of Compound 82 
This compound is analogous to 66 and as such should reveal the required information 
on the effects of the methyl group on hydrolysis. The compound was tested with 
boratefDMSO pH 8.75 in the same manner as previously discussed, there was no 
hydrolysis, even when the pH was raised to 10 and the reaction epindorph tube 
allowed to sonicate for 24 hours. This was a very interesting result and indicated that 
for hydrolysis of carbamates the nitro group is important. In order to confirm this the 
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hydrolyses of the acetals 73 and 81 were investigated. Figure 239 shows example 
HPLC profiles of both 73 and 81 these indicate that there is very little difference 
between the rate of hydrolysis of the methyl and nitro acetal analogues and it is onW 
when the diol is formed that differences in the rate can be observed. It also adds to 
the evidence suggesting that in the case of the carbamate both the nitro and hydroxyl 
function are needed to catalyse hydrolysis. 
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2.5.3 Use of the Turn group in peptides 
As the methyl derivative Tme was ineffective as a protecting group the Tnm group 
was reinvestigated. The lysine derivative 83 was synthesized in good yield by 










Figure 2.40 Synthesis of compound 83 
The test peptide Lys-Phe-Gly-Lys(Tnm)-Ala-Gly-Gly 84 was then synthesized as 
outlined in the experimental section. The peptide was subsequently acetylated with 
phenylacetic acid to give it an extended retention time on HPLC. This was 
particularly useful as a number of reactions would be performed in DMSO. As 
DMSO has a large solvent front it was helpful to have as large a retention time as 
possible so that the solvent front did not mask the compounds under study. 
After cleavage from the resin and purification, via semi-preparative HPLC, the 
peptide was tested for the lability of the lysine protecting group. 
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At pH 8.75 in DMSO/borax buffer (2:1) the protecting group was removed with 
sonication in less than 30 minutes. This was an excellent result and proved that the 
protecting group strategy could be used in a peptide situation. 
The removal of the protecting group was subsequently examined in a number 
solvents. 
2.5.4 Kinetics of hydrolysis of peptide 84 
As with 51 and 66 a series of kinetic experiments were performed at three different 
temperatures, the results of which are shown in graph 2.4. 
75 
Graph of Hydrolysis of Peptide 84 at three different temperatures 
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Graph 2.4 
The protected peptide appears to cleave at a similar rate to the test molecule 66 at 
37°C and 25°C but appears to be slower at 9°C. The reasons for this are uncertain 
although reduced solubility of the phenylacetylated peptide 84 at the lower 
temperature would seem to be the most likely cause. The comparability of the model 
compound and the peptide at the higher temperatures indicates there is no 
fundamental difference between the model and the real situation. 
2.6 Side products 
The problem of side products in the break down of the diol structure remains. While 
these can be kept to a minimum by using a high pH this is obviously not the desired 
answer. In an effort to find out what was taking place during cleavage, an 
experiment was designed using acetonitrile at pH 8 with borate buffer. These 
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conditions gave the highest proportion of side product in the shortest time. Once this 
unknown product had been produced it was isolated via semi-preparative HPLC. 
Having isolated the side product, attempts were made to break it down to give the 
free amine. The most promising results were achieved by stirring in Tris at pH 8.5. 
Figure 2.41 shows that the side product can be converted quite quickly to the desired 
amine, at least to a reasonable degree. Figure 2.42 which shows the side product 
after being stored for a week in a loosely stoppered bottle, indicates that the 
compound is only semi-stable and will in fact break down of its own accord with 
time. It is possible that the lack of cleanliness of the reaction may create problems 
when more than one lysine is protected, but this should not prove to be an 
insurmountable problem since the intermediate is intrinsically unstable. 
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2.7 Hydrolysis hypothesis. 
The experiments undertaken so far have elucidated a number of structural factors 
vital for the enhanced rate of base hydrolysis of the protecting groups studied. Table 































The enhanced rate of hydrolysis is only apparent when the OH and NO 2 groups are 
present in the carbamate situation. Although for esters the presence of the NO 2 group 
does not seem to be a necessity as cleavage can be achieved at an enhanced rate when 
the CH3  group is present. It seems likely, that for esters 51 and 64, the enhanced rate 
of hydrolysis can be accounted for by the Henbest-Kupan effect. The overall 








Hydrolysis of the carbamates 66 and 82 however, can not be accounted for solely by 
the Henbest-Kupan effect, since this does not take into account the difference in the 
CH3 and NO2  groups. In addition, it should be noted that whereas the ester 
compounds give a clean hydrolysis in all the basic buffers tested, the carbamate 
compounds produce side products in a number of solvent/buffer mixtures. These 
side products are likely to be formed by the reaction of intermediates, formed during 
the breakdown of the carbamate, and the buffer. 
Any hypothesis suggested for the mechanism of cleavage of the Tnm protecting 
group must be able to account for all these pieces of information. In an effort to 
elucidate what was taking place during cleavage of the carbamate 84, the side 
product isolated from the hydrolysis of 84, (section 2.6) was sent for mass spectral 
analysis. The result of which gave a mass of 900.37798 as opposed to 767.40426 for 
the completely deprotected compound. It is possible to draw a number of structures 
which will allow for the extra 133 mass units. The structure (86) shown in figure 
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Figure 2.44 
As aforementioned, such side products are not formed in the deprotection of esters 
(section 2.2) nor are they formed when Tris is used as the buffer (section 2.5). We 
can infer, therefore, that the side product is not formed via a reaction of a carbamic 
acid break-down product, since the acid functions are essentially the same in both the 









As the upper situation 
does not occur it seems 
unlikely that the lower one 
will. 
Additionally, since the stable intermediate is not formed when Tris is used as the 
buffer, it is likely that it is the product of a reaction of the borate and some reactive 
intermediate. There are several possible mechanisms which could account for this. 
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2.7.1 Hypothesis (A) 
One explanation is that the hydrolysis proceeds via an elimination mechanism not 
dissimilar to that of aromatic carbamates with strong leaving groups 21 ' 22 '23 ' 24 '25 . See 


















RNH2 + CO2 
Figure 2.46 EIcB mechanism for hydrolysis of carbamates 
If we apply this hypothesis to current situation it can be seen that the isocyanate 
initially formed could well act as a competitive substrate for the borate and OW 
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Figure 2.47 
If this occurred with peptide 84 it could account for a mass spectrum fragment of 
mass 900 (86). 
This hypothesis is however flawed since the isocyanate formed would likely react 
with any amine present or with Tris buffer to form a urea for which there is no 
evidence. Also the hypothesis does not explain the necessity for both OH and NO 2 
groups, since if the mechanism depended solely on the electron withdrawing effect of 
the NO2  group the acetal compound 73 should be hydrolysed at an increased rate and 
it is not. 
2.7.2 Hypothesis (B) 
In order to reconcile the Henbest-Kupan theory, which almost certainly operates in 
the case of the ester derivatives, with the situation present in the nitro carbamates, the 
following mechanistic path was devised. (See figure 2.48) 
In this theory the nitro group attacks the hydroxy imine, formed after initial proton 
abstraction, to yield a six member ring. This ring breaks up to yield a highly efficient 
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The route to the left involves an E1cB elimination mechanism whereas that to the 
right involves the BAC2  hydrolysis. As aforementioned, the lack of urea formation 
when Tris buffer is used tends to suggest that the mechanism does not involve an 
isocyanate intermediate. This coupled with the fact that borate could easily replace 
the OH in the right hand route of figure 2.48 to give the semi-stable intermediates 86, 
which have been found to be formed during hydrolysis of the carbamates, suggests 
that the right hand route may be the more likely. Hypothesis B also offers an 
explanation of why both OH and NO 2 groups are needed for hydrolysis of the 
carbamate to take place. 
The hypotheses A and B are attempts to logically explain a set of observed 
phenomenon, hypothesis B perhaps offers the most convenient answer but it is by no 
means certain that the mechanism follows this route, indeed it would be foolish to 
state that one mechanism is correct since there is insufficient evidence to settle the 
matter. NMR experiments on the test compound 89 were undertaken in an attempt to 
shed further light on the mechanism of hydrolysis. These however proved 
inconclusive primarily due to a large water peak from the buffer obscuring the area in 
the spectrum of most interest, making it difficult to follow the reaction. 






2.8 Thermodynamic considerations 
In an effort to shed further light on the mechanism of reaction, the kinetic data from 
the hydrolysis of 51 and 66 was used to calculate the value of a number of 
thermodynamic variables. Before this is discussed however, it must be pointed out 
that as only three temperatures were used the results from any such calculation must 
be fraught with.error. Several problems occurred in the measurement of data, 
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notably the difficulty in maintaining constant temperature under the conditions used 
i.e. in a sonic bath. This made it impractical to take readings at anything less than ten 
degree intervals. The physical properties of DMSO, its viscosity and freezing point, 
also made readings difficult, as did the speed of reaction. As previously mentioned 
however, the objective of the exercise was to look at rates under optimised 
experimental conditions. Taking these points into consideration, it is still possible to 
arrive at approximate estimations of the entropy and enthalpy of activation for 
hydrolysis. 
The Arrhenius equation k=A .e RT shows the relationship between activation energy, 
rate and temperature. It is possible however to derive an expression which relates 
temperature and rate to the entropy and enthalpy of the activated state of reaction this 
expression is termed the Eyring equation 26 . 
k=k8T/h .eA5* .e *T. 
k-Rate constant, k8=Boltzmann constant, h=Planks constant, R=universal gas 
constant, T=Temperature. 
This expression can be expressed logarithmically as. 
ln(k h/k8 T)=AS4IR - AH4/RT 
This is a linear equation of the form of Y=A+BX. 
where Y= ln(k h1k8 T) 
A= AS 4IR 
B=-AH 4/R 
X= 1 /T 
Hence a plot of X V's Y should give a gradient equal to - AH 4/R and an intercept of 
AS 4 /R graph 2.5 shows the Eyring plot for 51 and 66 respectively. Giving a 







Although as previously mentioned it is dubious to quote results derived from such a 
limited pool of information, as the error bar included on the graph indicates. It is 
however interesting to note that the entropy of activation S*  value for the carbamate 
is positive while that for the ester is negative. Work by Christenson 25  on the 
hydrolysis of carbamates suggests that hydrolysis by the E1 cB mechanism has a 
positive entropy value. Whereas the hydrolysis of most carbamates and esters via the 
BAC2 mechanism involves a negative entropy, as is shown in table 2.6 and found by 
Bruice and Fife 9 when investigating the Henbest-Kupan effect 8 '9". This perhaps 
adds further weight to the suggestion that there are different mechanisms of 
hydrolysis operating in the ester and carbamate situations. 
Thermodynamic data for the alkaline hydrolysis of selected esters and carbamates is 
shown in table 2.6. 
87 
Table 2.6 from Patai27 & Christenson 
25 
2.9 Mechanistic comments 
2.9.1 Esters 
It seem likely that in both the Tnm and Tme derivatives the rate enhancement is due 
to the Henbest-Kupan effect. The True derivative having a faster rate of hydrolysis 
than the Tnm due to partial ionisation of the Trim or some other process whereby 
interaction of OH and NO 2  groups hinders the anchimeric assistance. The situation 
as regards borate has already been discussed, and it may well have a catalytic effect. 
The hydrolysis of the diol compounds does however proceed at an accelerated rate 
even without its presence so any effect is likely to be an enhancement of effects 
already present rather than a special effect 
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2.9.2 Carbamates 
As has been illustrated it is possible to write a number mechanisms which will 
account for the hydrolysis of the Tnm derivative at enhanced rate. The 
thermodynamic data while interesting, is dubious in nature, so it is difficult to 
propose an E1 cB over a BAC2 hydrolysis mechanism on this evidence alone. The 
lack of urea formation suggests that an isocyanate is not formed during cleavage 
which would suggest a BAC2 mechanism. It is impossible with the evidence available 
to be certain one way or the other, what is certain however is that the NO 2 and OH 
groups interact in some way to enhance the rate of hydrolysis. 
2.10 Protection of a large peptide Ub 36-76 (90) 
As a crucial test, lysine (63) of the Ubiquitin fragment 36-76 (90) was protected with 
Tnm. This would prove to be a particularly useful target since the fragment had 
already been synthesised with the penicillin acylase cleavable 4-hydroxyphenylacetyl 
protecting group 28 . Removal of this protecting group by enzymatic means had not 
been achieved probably because tertiary structural interactions cause the lysine 
residue to be sterically hindered and therefore unable to fit into the active site of the 
enzyme. Attempts in the group were made to denature the target peptide and hence 
better present the lysine to the enzyme. This was however largely unsuccessful and 
presents a flawed strategy since conditions which denature the target peptide are also 
likely to denature the enzyme. 
If the Tnm protecting group could succeed on a relatively large peptide, where 
enzyme-cleavable groups had failed, its utility would be proved and its use in the 
fragment coupling approach could be considered. 
The peptide was synthesised as outlined in the experimental section without any 




It was decided to purify the peptide via the Tbfmoc29 91 affinity purification group 
since this was likely to be the W protecting group used in any subsequent fragment 
couplings. 
Figure 2.50 
The Thfmoc group was utilised in both of the relevant purification protocols 
developed in this laboratory. Firstly as a hydrophobic group to extend the retention 
time of the peptide on HPLC and thus make the separation of truncations much easier 
via semi-preparative HPLC. And secondly by affinity binding to porous graphitised 
(PGC). This is a novel protocol whereby the impure Thfmoc-peptide is vortexed in 
solution with some PGC, the carbon adsorbs the large flat Thfmoc group causing the 
labelled peptide to become stuck to it. The truncations formed during synthesis lack 
Thfinoc and can easily be removed by washing. Once the truncations have been 
removed the peptide is liberated from the carbon by cleavage with piperidinefDMF. 
In accordance with the first of these methods the peptide N-terminus was 
protected with Thflnoc and subsequently purified by semi-preparative HPLC. The 
Trim and Thfmoc protecting groups removed by borate buffer pH 8.75 in DMSO 
(1:2) in under 30 minutes. The DMSO was subsequently removed in vacua, the 
peptide gel filtered and freeze dried to give the desired product. 
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Figure 2.52 Removal of Tnm & TbFmoc 	Figure 2.53 Dual injection of 
peptidprotecting groups by sonicating peptide 90 after deprotection 
for 30 mins in pH 8.75 borate / DM50 	& a known sample of Ub36- 76 
L1I 
The second purification strategy worked equally well and is in some ways superior 
the Tbfmoc and Turn protecting groups being removed by vortexing the carbon with 
10% piperidine in 1:1 6M Guanidine.HC1/propan-2-ol. This solution is then 
neutralised, concentrated in vacuo and gel filtered to give pure Ub 36-76. It is worth 
noting however that although the vortexing only takes approximately 5mins the pH at 
this time may be as high as 13 or 14. 
It can be seen then, that the Trim protecting group satisfies the criteria earlier set out 
for a post cleavage protecting group (section 1.5) and should be compatible with the 
hydrazide fragment coupling strategy. Recent work 
31  in this laboratory indicates that 
the this is indeed so. The successful coupling of two small peptides using the azide 
method (section 2.1.2) one of which contained a lysine protected with Trim has been 
achieved. 
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CHAPTER 3: SYNTHETIC PEPTIDES AS VACCINES AGAINST 
HIV INFECTION 
3.1 Immunology: A brief survey 
The immune systems which operate in living organisms are some of the most 
complicated and least understood in all biology. Having said this they can broadly 
speaking be separated into two distinct branches, the humoral response and the cell-
mediated response. 
3.1.1 Humoral response 
The humoral response is centered around the production of neutralising antibodies. 
In this process an antigen is first recognised as foreign by a macrophage which 
engulfs it and packages its coat proteins so that they are expressed on the surface of 
the macrophage. These packaged antigens are then recognised by both B-cell and 
TH-cell receptors. The B-c ells are stimulated by the T a-cells to enlarge and divide 
forming a population of antibody secreting plasma cells and a smaller number of 
memory cells. These secreted antibodies then recognise and neutralise the invading 
antigens directly. Memory cells are long lived cells which lie dormant, on a second 
exposure to the antigen however they are quickly transformed into plasma cells and 
begin secreting antibodies. 
3.1.2 Cell mediated response 
The cell mediated response refers to actions of the immune system whereby cells of 
the immune system are actively involved but antibody production is of minor 
importance. The cell mediated response involves two major classes of lymphocytes. 
Cytotoxic Tc-cells  recognise antigens on the surface of infected cells and lyse those 
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cells. Natural killer cells on the other hand, are able to kill foreign cells without the 
necessity of a packaged antigen for recognition. 
T-lymphocytes, macrophages, other leukocytes, and natural killer cells can also act to 
eliminate invading micro organisms and other foreign material by releasing 
lymphokines. These proteins act in stimulating and regulating the immune 
responses, they also act to induce inflammation and as toxic proteins for tumor cells. 
Figure 3.1 shows how the various facets of the immune system are linked. 
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Figure 3.1 
3.2 Vaccines 
Antigens within the body are in the main recognised by their surface characteristics. 
As the surfaces of many infectious agents are predominantly proteinous in nature, it 
is these surface proteins, which, by inducing recognition by B and T cells elicit the 
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body's defences. Since it is often only particular areas of these proteins that induce 
this effect it is often possible to synthesise relatively short peptide sequences which 
posses the important moiety of the larger protein molecule. It is this principle that 
underlies the use of synthetic peptides as vaccines. 
To date, most vaccines are whole inactive or live attenuated vaccines, the 
whole infectious organism being used as the vaccine particle. The use of a live virus 
guarantees a natural presentation of immunogens and has a historical background 
stretching back over almost two hundred years. Edward Jenner first used the live 
cowpox virus as a vaccine against the far more dangerous, yet related, smallpox in 
1798. There is however not always a conveniently related live virus and the use of 
attenuated viruses has inherent risks. In any rapidly mutating virus and in particular 
with retro viruses such as HIV, the risk that an attenuated virus acting as a vaccine 
could revert to a viable form is a constant worry. Retroviral replication involves 
chromosomal integration in the vaccine recipient and may establish life long 
persistence. Transmission to others cannot be ruled out and transient episodes of 
immunosuppression have to be anticipated. The use therefore of a subunit or 
synthetic vaccine is particularly attractive for combating HIV. 
As synthetic molecules, peptide vaccines have a low inherent risk, it is also possible 
to exclude immunosuppresive and infection enhancing epitopes which may be 
present on the native virus. One of the difficulties however may be the inclusion of 
adequate B and T-cell epitopes. This however may be overcome by immunisation 
with a cocktail of peptides each representing a number of epitopes. So far peptides 
have only been of limited use for immunisation
1,2 . However they represent a 
relatively new field and it is likely that with time will become a more useful form of 
vaccination. 
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3.3 Human Immuno deficiency virus (HIV) 
3.3.1 introduction 
Human Immune Deficiency Virus (HIV) is the causative agent of acquired immune 
deficiency syndrome (AIDS) 3 '4 . AIDS is a disease of the immune system 
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Although the main point of entry for infection is through CD4+ve lymphocytes (TH 
helper cells)6  the virus also affects other CD4 bearing cells such as macrophages 
There is also evidence to suggest that the virus can enter cells which do not possess 
the CD4 receptor. 8  although this is generally thought to be of secondary importance. 
Current theories  on the progress from HIV positive status to the onset of full blown 
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AIDS suggest that there is a rapid turn over of virus and infected cells.' 
0,11,12  the 
immune system eventually being overcome resulting in death from opportunistic 
infections. This is in contrast to the previously held view which suggested that HIV 
infection was a relatively indolent process during the extended period of clinical 
latency' 3 . 
There are two main subtypes of HIV, termed HIV-1 and HIV-2, these two types are 
prevalent in two different geographical areas HIV-1 being predominantly associated 
with the USA and Western Europe 
13,  whereas HIV-2 is mainly a disease of the 
African continent 13. These two strains have approximately 40% homology 
14  between 
their envelope coat proteins. There are also animal versions of HIV such as the 
simian version (SlY), and feline version (Fly), both have proved useful models for 
researchers' 5 " 6 . 
3.3.2 Structure 
HIV (figure 3.3) is a retrovirus, its genetic make up consisting of viral RNA which 
codes for two structural genes gag (internal) and env (envelope) glyco-proteins, and 
the regulatory genes pol, vif, vpr, rev, tat, and ref. The outer layer of the virus 
consists of envelope comprising a host derived lipid bilayer, interspersed with a 
glycoprotein. This protein, is translated as a 88Kd precursor that is subsequently 
modified by glucosidase 1 to give a 1 6OKd glucosylated molecule. This, so called 
Gp160, is cleaved by a cellular protease during virus maturation to the external 
envelope protein 0p i20, and the transmembrane protein Gp41. Gp41 anchors 
Gp120 to the virus through non covalent interactions. The Gp120 molecule, is the 
recognition site to which CD4 receptors on TH lymphocytes 
17  bind during viral entry 
into the host cell. 
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3.3.3 Viral replication 
The virus becomes attached to T H  cells via the affinity of CD4 to op1 20.18 The 
method by which the viral and host membranes then fuse to allow viral RNA into the 
host cell is not fully understood' 9-25 . Once the viral RNA has entered the host cell 
however, it is quickly transcribed into DNA by reverse transcriptase and incorporated 
into the hosts genome. This DNA is then read by the normal transcribing apparatus 
of the host cell and produces viral proteins and RNA. These proteins and RNA, are 
then assembled and bud off from the surface of the host, acquiring host lipid bilayer 
as they do so. (Figure 3.4) 
17 
1) Attachment, 2) Uncoating, 3) Reverse transcription, 4) RNASEH Degredation, 5) DNA synthesis 
of second strand, 6) Migration to nucleus, 7) Integration, 8) Latency, 9) Viral transcription, ID) RNA 
nuclear transport, 11) Protein synthesis, 12) RNA stability, 13) Protein glycosylation, 14) RNA 
packaging and virion assembly, 15) Release of the virus, 16) Maturation, 17) Other. From ref 7 
Figure 3.4 
3.3.4 Gp 120 
In order to develop a successful vaccine it seems likely that the interaction between 
GP120 and CD4 must be blocked, as this interaction is fundamental to disease 





would block the binding of Up120 to CD4. In addition, a vaccine should also affect 
a cytotoxic T-cell response which will neutralize viral particles. 
Gpl2O is a l20Kd glycosylated protein (figure 3.5), it consists of a number of 
distinct regions which have been studied and mapped extensively 2628 . The regions 
of Gpl2O can be divided into two distinct sub sets, the conserved regions, and the 
variable regions. The variable regions V1,V2,V3,V4,V5, are regions of the protein 
Nry high mannose 	complex 
Figure 3.5 Gp120 
101 
where the amino acid sequence is highly variable between strains. The V3 loop, one 
of the variable regions, is the immuno dominant epitope of the GP 120 molecule. 
This means to say, if antibodies are raised against Gp120 they will in the main be 
composed of antibodies which recognise the V3 loop. Although immunisation with 
synthetic peptides mimicking the V3 loop has had some success in chimpanzees, 29,30 
it seems unlikely that a vaccine based on such a variable region would have sufficient 
cross reactivity to offer any degree of protection in the real world. Interestingly the 
tip of the V3 loop G,P,G,R is in fact fairly well conserved 3 ' and has been implicated 
in secondary binding processess 30 '32 . On the whole however the V3 loop is thought 
to be a poor target for vaccine studies due to its excessive variability. The conserved 
regions of the Gp120 molecule would obviously make better targets since they show 
less strain variance. One conserved region of the GP120 molecule which has been 
shown to elicit neutralising antibodies is the CD4 binding region 33 . The highly 
conserved nature of this region and the fact that it is involved in binding to CD4 
make it an ideal vaccine target. By removing the CD4 binding region from the whole 
of Gp 120 the problem of the immunodominance of the V3 loop should be 
circumvented. 
3,3.5 CP120-CD4 binding 
The C4 region ofGpl2O is important in binding of CD4, the binding site is however 
a discontinuous site involving linearly separated amino acids which are spatially 
proximal in the three dimensional structure. This binding site for CD4 involves a 
number of highly conserved amino acids which have been identified by point 
mutations as being vital for binding. The residues Thr-257, Asp-368, Glu-370, Asp-
457 and Trp-427 are believed to be amongst the most important. It was originally 
thought however, that the C4 region was in itself the binding site, as a deletion 
mutation lacking this area did not bind to CD4 17. The C4 region has also been shown 
to be exposed on the surface of the native protein 
34  strengthening the evidence behind 
it being involved in binding. The residue Trp-427, was initially implicated in 
binding 31,16  but it is now thought that it may not be involved in actual contact. 
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Rather that its presence is crucial to a flip from n-sheet to a-helix, which occurs on 
moving from a polar to a non-polar environment. It is thought that this flip is 
necessary for CD4 binding to take place". 
3.4 Discontinuous epitopes 
The obvious problem in trying to synthesis a molecule which mimics a discontinuous 
epitope is the problem of trying to bring together the amino acids involved in binding 
in such a way that they mimic the structure of the natural binding site. Without a 
crystal structure (which currently does not exist for Up 120) the shape of the binding 
site can only be guessed through the empirical evidence supplied by point mutation 
studies. Earlier work in this laboratory 38  in the area of discontinues epitopes has 
sought to utilise a Cys-Val-Cys construct to bring together linearly separated 
sequences, which, through a disulfide bond are proximal to one another in the natural 
structure. Some success has been achieved through the synthesis of the GC  peptide 
(figure 3.5), a highly immunogenic peptide involving amino acids important for CD4 
binding. 
Figure 3.5 GCJ 
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The initial aim of this project, was to use the Cys-Val-Cys technique to synthesis a 
number of other peptides corresponding to discontinuous epitopes. Antibodies 
would then be raised to these synthetic peptides, and binding studies with CD4 and 
Gp120 carried out. 
3.5 Discussion 
3.5.1 Introduction 
The first peptide to be synthesised in this program was a 31 amino acid sequence 
comprising the C4 region (figure 3.6). This peptide 92, contains the 
WQEVGKAMYA sequence, which has been identified as being exposed on the 
surface of natural Gp120 34 . The presence of the Trp-427 residue, which is important 
for the switch from n—sheet to a-helix that is involved in the binding of CD4 to 
Gp120 is also important. It was hoped that after a successful synthesis of this 
peptide, a larger structure involving the GC 1 amino acids might be constructed 
(figure 3.7). This would enable the immunogenically important amino acids of both 
structures to be present in the same molecule and hence increase the chances for 




Figure 3. 7 
3.5.2 Synthesis of C4 peptide (Acm protected) (92) 
The 31 amino acid peptide GGEFFYCVCRIKQFINMWQEVGKAMYAPPISG 92 
was synthesised as outlined in the experimental section using Acm protection for the 
cysteine residues. The Acm protected peptide was purified using reverse phase semi-
preparative HPLC. There were some problems during purification due to the 
insolubility of the peptide. It was however, possible to produce purified, protected 
peptide, in reasonable yield (200mg resin yields 40mg of Acm peptide). 
In order for the peptide target to have the correct structure the disulfide bond 
between the two cysteines must be formed. For this to happen, the Acm protecting 
groups must be removed and the sulfur bond formed under oxidising conditions. The 
removal of the Acm group was first attempted using Mercury (II) Acetate 39  as 
outlined in the literature. This initial procedure proved ineffective so a second 
attempt was made using a vast excess of the reagents (see experimental). This 
second attempt, after work up, revealed a change in the HPLC profile. Mass 
spectroscopy of the major peak suggested a situation whereby only one Acm had 
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Figure 3.8 
The single deprotected Acm peptide was purified and the Mercury (H) acetate 
deprotection protocol attempted a second time. HPLC analysis of the resultant 
product indicated no change in retention time, mass spectra confirmed the single 
deprotected species as being the major component. This was a somewhat curious 
result as Acm deprotection via Mercury (II) acetate has been reported in the 
literature 39  and used in this laboratory for a number of years. 
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NHCOR1 ± Hg(SC2H40H)2 
Figure 3.9 suggested mechanism for Mercury(H) Acetate/Mercaptoethanol 
deprotection 
It was thought that the deprotection reaction was failing due to some steric effect 
hindering the access of the Hg(OAc) 2 to the Acm group. In an attempt to overcome 
this problem the reaction mix was place in sonic bath at 40°C overnight. On 
inspection of the resultant mixture by HPLC two distinct peaks could be seen. The 
mass spectrum of these two peaks indicated that the peptide had been broken up by 
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the overnight sonication in to two smaller fragments. Interestingly, the mass 
spectrum of one of these fragments showed a distinctive pattern which could be 
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Figure 3.10 
After this failure the mercury (II) acetate protocol was abandoned and replaced with 
the silver trifluromethanesulphonate 4° reagent (see experimental section). Removal 
of the Acm groups using this reagent also proved unsuccessful. Literature precedents 
exist for the removal of the Acm group using iodine 4 ' and Ag/BF442 . Iodine was 
used in an attempt to remove the Acm groups, but the reaction resulted in iodination 
of the tryptophan ring so this method was abandoned. 
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Clearly there are considerable difficulties present in the efficient removal of the Acm 
group from this problematic sequence. It was hence decided to re-make peptide 92 
using tBuS as the protecting groups. 
3 5.3 C4 peptide (thuS protected) (93) 
The tBuS protected peptide 93 was synthesised as out lined in the experimental 
section, purification via HPLC proved extremely difficult due to solubility problems. 
It was therefore decided to remove the tBuS protecting groups prior to purification, 
in order to aid solubility. This was achieved using the 
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Figure 3.11. Removal of tBuS group using trialkylphosphine/water 
This method did remove the tBuS groups, although the resultant peptide was still 
very insoluble, and exceptionally difficult to work with. On average 90-95% of 
peptide was lost when purifying the crude tBuS free peptide. 
Various attempts were made to oxidise the sulfur bond in the deproteeted peptide, 
both in pure form, and crude form, none of these was however successful. Failure 
being confirmed by unchanged HPLC profile, positive Ellman's 44 test and mass 
spectroscopy. 
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3.5.4 C4 peptide [Pro (D)Val] (94) 
In order to aid oxidative formation of the disulfide bond the Cys-Val-Cys bridge 
present in peptide 93 was replaced with the n-turn mimic Cys-Pro-(D)Val-Cys in 
peptide 94. This structural replacement has been found to encourage the oxidation of 
disulfides45 . 
The peptide was synthesised as outlined in the experimental section, the 
change in sequence having little effect on the overall synthesis. Removal of the tBuS 
groups was achieved using the tributylphosphine technique as with peptide 93. 
Purification of the deprotected peptide proved exceptionally difficult, solubility again 
being a major problem. 
Oxidation was again attempted with very limited success. It was possible to oxidise 
the peptide using DMSO at pH4, however this also resulted in oxidation of the 
methionine residues present in the sequence. In addition, the dramatic losses of 
peptide during HPLC purification due to very poor solubility, made it impossible to 
attempt to reduce the methionines as there was simply too little product by this stage 
of the purification process. Due to the extensive practical problems and uncertainty 
in immunogenicity of the product, this work was abandoned with a view to returning 
at a later date. 
3.6 Conclusions and summary 
The insolubility of the chosen sequence dramatically hindered the purification of the 
desired peptide. A somewhat unusual situation prevailed, whereby the removal of 
the cysteine protecting groups did not actually aid solubility. This made it practically 
impossible to arrive at purified oxidised peptide. There is always a possibility when 
one synthesises unnatural peptides that the desired sequence will be problematical. 
The use of a n-turn mimic such as cyclopentyl was mooted as a way around the 
difficulty of forming sulfur bridges, although these compounds were latter found to 
be non-immunogenic and therefore effectively pointless for our studies. The 
problem in purification is caused by the dramatic losses at each HPLC stage, hence it 
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would be necessary to reduce the number of HPLC steps to a minimum in order to 
produce the desired product. Although the development of a reliable, solublising, 
cysteine protecting group would certainly aid the synthesis of this troublesome 
peptide, it is the intrinsic insolubility of the molecule which causes problems. 
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CHAPTER 4: EXPERIMENTAL 
4.1 Notes 
All amino acids were purchased from either Bachem, Novabiochem, or alternatively 
were synthesised as outlined in the text. They were all of the L configuration unless 
otherwise stated. Melting points were determined using a Koffler hot stage melting 
point apparatus and are uncorrected. Optical rotations were measured on an AAI 000 
polarimeter (Optical activity limited) using a 10.0cm cell in the solvent indicated in 
the text. Analytical thin layer chromatography (t.1.c) was carried out using a 0.3mm 
layer of silica (Merck, kieselgel 609) containing 0.5% Woelm fluorescent indicator, 
on foil plates in the solvents indicated in the text. The components were observed 
under ultra-violet light, by reaction with iodine vapour and by charring of the plate 
after spraying with 20% sulphuric acid in methanol. Infrared spectra were recorded 
on a Bio-RAD SPC 3200 instrument. Ultraviolet spectra were recorded on a Varian 
Cary 210 spectrophotometer in the solvents indicated in the text. High and low 
resolution fast atom bombardment (FAB) mass spectra were measured on a Kratos 
MS50TC instrument, using either thioglycerol, 3-nitrobenzyl alcohol or glycerol as 
matrix. Nuclear magnetic resonance (NMR) spectra were recorded on either a Jeol 
FX-60 (60MHz), a Brucker WH-80 (80MHz), a Brucker WP-200 (200MHz), a 
Brucker AC-250 (250MHz), a BruckerWH-360 (360MHz) instrument in the solvents 
stated. Elemental analyses were performed on a Perkin-Elmer 2400CHN analyser. 
Amino acid analysis was performed on a LKB 4150 alpha amino acid analyser on the 
hydrolyse obtained after heating samples at 110°C for 24 hours in a sealed Carious 
tube, followed by evaporation to dryness. 
All solvents were distilled before use and the following were dried using the 
reagents given in parenthesis when required: dichloromethane (calcium hydride), 
diethyl ether (sodium wire). Peptide synthesis grade dimethylformamide (DMF), 
1 ,4-dioxan and piperidine were obtained from Rathburn Chemicals, Walkerburn 
Scotland. Peptide synthesis grade trifluroacetic acid was obtained from Applied 
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Biosystems (ABI). High performance liquid chromatography (HPLC) was carried 
out using either an ABI system, comprising 2 x 1406A solvent delivery systems, an 
1480A injector/mixer and an 1783A detector/controller, or a Gilson system, 
comprising 2 x 306 solvent delivery systems, an 81 1C dynamic mixer, an 805 
manometeric module, a 119 UVIVIS detector and Gilson 715 or Unipoint software 
driven gradient controller. Components were eluted from various columns, as 
described in the text, by a linear gradient of acetonitrile (far UV grade, Rathburn 
Chemicals) in Milli-Q grade water, where both solvents contained 0.1% v/v of HPLC 
grade trifluoroacetic acid (Fisons). 
4.2 Solid phase peptide synthesis. 
The polypeptides described were synthesised on an Applied Biosystems 430A 
automated peptide synthesiser fitted with a UV monitoring system as described 
previously'. All peptides were synthesised using the 9-fluorenylmethoxycarbonyl 
(Fmoc) strategy of Na protection. This involves the complementary use of 
orthogonal acid labile side chain protection and an acid labile peptide-resin linker. 
The side chain protecting groups used were as follows : t-butyl (Bu) ethers for 
serine, threonine and tyrosine; t-Bu esters for aspartic and glutamic acid; t-
butoxycarbonyl (Boc), 1,5 -dioxaspiro-5:5undecane-3-nitro-3-methoxy carbonyl  
(Tnm) for lysine; t-triphenylmethyl (trityl) for histidine; (Pmc) for arginine. The 
carboxamide side chains of arginine and glutamine were incorporated as either the 
4,4'-dimethoxybenzhydryl (MBH) or trityl derivatives, or without side chain 
protection as indicated in the text. Cysteine was incorporated as indicated in the text. 
4.2.1 Coupling of the C-terminal amino acid onto 4-alkoxybenzylalcohol (Wang) 
resin. 
A solution of Fmoc amino acid (1mM) and N,N'-diisopropylcarbodiimide (DIC) 
(0.5mM) in DMF (20ml) was stirred for 15 minutes at room temperature, then 4-
benzyloxybenzylalcohol functionalised polystyrene resin (Wang) (1.0g, 0.8mM) was 
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added, together with a catalytic amount of 4-(N,N'-dimethylamino)- pyridine and the 
mixture was then sonicated for 1-2 hours. The functionalised resin was then 
removed by filtration and sequentially washed with DMF, 1,4-dioxan and 
dichioromethane, before being dried under a vacuum. The loading of the 
functionalised resin was then determined by treating a known weight of resin with 
20% piperidine/DMF in a 1 Oml volumetric flask, for 20 minutes in a sonic bath. The 
UV absorbance of the supernatant was then measured at 302nm and the loading 
calculated using the Beer-Lambert law (302= 15400 for fUlvene-piperidine adduct). 
This procedure generally gives a resin with a functionality in the region of 0.1 mm/g. 
To obtain higher resin loadings (0.5-0.6mMIg), the amounts of Fmoc amino acid and 
DIC were increased to 5.0mM and 2.5mM respectively. 
4.2.2 Automated SPPS 
Synthetic procedures were pre-programmed into the ABI 430A synthesiser prior to 
the commencement of synthesis. Routinely most residues were incorporated using 
double couple cycles, in which the first coupling cycle utilised a preformed 
symmetrical anhydride, followed by the second coupling using a preformed 1-
hydroxybenzotriazole (HOBt) ester. The exceptions to this were the amino acids 
asparagine, glutamine and histidine, which were coupled twice via their HOBt esters 
and glycine, which was coupled singly as a symmetric anhydride. An alternative 
coupling strategy was used for the peptides 84, 90, 99 whereby the amino acids were 
all single coupled using the HOCt 2 activating agent. 
1. Capping - The resin was vortexed with a solution of 20% piperidine/DMF for 3 
minutes before being drained. An aliquot of the deprotection solution was then sent 
to a UV detector in order to quantify the amount of fulvene-piperidine adduct present 
and hence subsequently gave an indication of the percentage incorporation of each 
residue. Deprotection was then repeated for a second time for one minute in order to 
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establish if the Na  protecting group had been completely removed. Finally the resin 
was washed with six portions of DMF/ 1 ,4-dioxan (1:1). 
3. Coupling-(I) The resin was vortexed with a solution of 0.5mM Fmoc amino acid 
preformed symmeterical anhydride (formed from 1mM Fmoc AA and 0.5mM DIC in 
the activator vessel). The first coupling cycle was allowed to continue for 30 minutes 
before the solution was drained from the reaction vessel and the resin washed with 
two portions of DMF. The resin was then vortexed for a second 30 minute period 
with 0.5mm of Fmoc amino acid HOBt active ester (preformed from 0.5mM Fmoc 
amino acid, 0.5mM HOBt and 0.5mM DIC) before being drained and washed with 
four portions of DMF. For certain difficult couplings the coupling cycle time was 
extended. 
(II) The peptides synthesised using the HOCt activating agent used a slightly 
different coupling cycle. Each cartridge contained 1mM of Fmoc amino acid and 
1mM of HOCt, the mixture was dissolved up in 4mls of DMF and passed to the 
activation vessel. The activation vessel contained 1mM of DIC dissolved in 4mls of 
1 ,4-dioxan, both mixtures were vortexed together for 20 minutes to form the 
activated ester. The mixture was then passed to the reaction vessel and vortexed for 
30 minutes before being drained and washed. 
4.3 Ellman's assay for free thiol groups 
Qualitative Eliman's assay  enables the number of free thiols per molecule to be 
calculated. Accurately weighed peptide (0.02-0.05 jsmol) is dissolved in 0.1M 
sodium phosphate buffer pH 7.3 (2.5 ml), containing 0.01M EDTA and 6M GdmCl. 
A fresh solution of 3mM 5,5'-dithiobis-(2-nitrobenzoic acid), (DTNB), in 0.1 M 
sodium phosphate buffer pH 7.3 is prepared. Denaturing buffer (2.5 ml) is placed in 
the reference cell and denaturing buffer plus peptide placed in the sample cell of a 
liv spectrometer. DTNB solution (100 jal) is added to each and mixed by inversion, 
the absorbance at 412nm is then recorded after a few minutes. The concentration of 
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free thiols can then be calculated knowing c 412 of nitrothiobenzoate (NTB) in 6M 
GdmCl is 13700 M 4 cm 1 . 
4.4 Kinetics 
The mechanical processes involved in the taking of kinetic data are described in 
chapter 2, as is the primary mathematical manipulation. Each kinetic run was 
performed at least twice and the data points averaged to reduce errors. The graphs 
presented in the text were produced using Micro Soft Origin software, the curves 
being modelled to the A. exp(-A 1 t) function. 
4.5 Synthesis 
iw 	 S 
Benzaldehyde (106.12g. 1M) was added to a solution of 
tris(hydroxymethyl)nitromethane (151.1 2g 1 M) in a solvent mix consisting of water 
(1 OOml), concentrated hydrochloric acid (80m1) and methylcellusolve (1 OOml), after 
the addition the mixture is made up to 500ml with more water. The reaction mixture 
is then shaken at room temperature for 40 hours. The white solid obtained is washed 
neutral with water. Recrystallisation from aqueous ethanol gave the title compound 
as a white solid (172g, quantitative); m.p. 125-126°C (lit., 4 125-126°C); (found: 
C,54.99;H,5.71 ;N,5.62, C 1 1 H 1305N requires: C,55.23;H,5.44;N,5.85%); t.l.c. (ethyl 
acetate/hexane, 3:7) Rf 0.47; u m (nujol) 3406 (OH), 1544 (NO2); 3H(CDC1 3 , 
200MHz) 7.36 (5H, s, aromatic); 5.65 (1H, s, benzylidene CH); 5.59 (1H, t ,OH); 
4.74 (2H, d, equatorial ring pair 2CH); 4.24 (21-1, d, axial ring pair 2CH); 3.72 (2H, d, 
CH20H); &C(CDCI 3  200MHz) 137.77 (aromatic quaternary); 129.43, 128.49, 
126.41, (aromatic CH);100.88 (benzylidene CH); 88.46 (aliphatic quaternary CH); 
68.56 (2 ring CH2's); 62.67 (CH20H); mlz (FAB)240 (MH+), HRMS found 
240.08637, C 11 H, 305N requires 240.08720 
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Benzaldehyde (53.06g, 0.5M) was added to a solution of tris(hydroxymethyl)ethane 
(61g, 0.5M) in a solvent mix consisting of water (SOml), concentrated hydrochloric 
acid (40ml) and methycellusolve (50m1), after addition the mixture was made up to 
250ml with more water. The white solid obtained was washed neutral with water. 
Recrystallisation from aqueous ethanol gave the title compound as a white solid 
(103g, quantitative); m.p 87-89 °C (lit., 5 87-89°C); (found: C,69.07;H,7.90, C 12H 1603 
requires: C,69.23;H,7.90%); t.l.c. (ethyl acetate/hexane, 3:7); Rf 0.56, um (nujol) 
3490 (b, OH); 8H(CDCI3, 250MHz) 7.50-7.46 (51-1, m, aromatic); 5.41 (1H, s, 
benzylidene CH); 4.03 (21-1, d, J 11.81, equatorial ring pair 2CH); 3.81 (21-1, d, 
CH20H); 3.62 (2H,d, J 11.81, axial ring pair); 0.74 (31-1, s, C113); 8C(CDCI3 
200MHz) 137.90 (aromatic quaternary); 128.73, 128.03, 125.83, (aromatic CH); 
101.46 (benzylidene CH); 72.94 (ring CI-1 2 's); 64.84 (CH20H); 34.61 (aliphatic 
quaternary CH); 16.62 (CH 3); mlz (FAB)209 (MH4 ); HRMS found 209.11754, 
C 12H 1603 requires 209.11777 
ii Lii 	 5R 	 H 
Cyclohexanone (40ml, 0.38M) and tris(hydroxymethyl)ethane (45.6g, 0.38M), plus a 
catalytic amount of p-toluenesulphonic acid (TsOH) were refluxed in toluene, 
overnight, using a Dean Stark apparatus. After 24 hours, the solution was cooled to 
room temperature, washed with water (2 x 1 OOml), and the organic layer dried over 
MgSO4 . Concentration in vacuo gave a white solid, recrystalization from 
hexane/ether gave the title compound.(66g, 86%); m.p. 60°c (lit'., 60-61°C); 
(found:C,66.33; 1-1,10.25%, C 1 1 H2003 requires:C,65.98; H,10%); t.l.c.(ethyl 
acetate/hexane, 3:7) Rf 0.48; u(nujol) 3417 (OH); 8H(CDC1 3, 200MHz) 3.60 (21-1, 
s, CH20H); 3.57-3.59 (41-1, d, J 2.63 Hz, dioxane ring CH 2); 2.85 (1H, s, OH); 1.79-
1.34 (1 OH, m, aliphatic ring CH2); 0.75 (31-1, s, CH 3); 5C(CDCI 3 50MHz) 97.80 (ring 
junction aliphatic quaternary); 65.46 (CH20H); 65.19 (2 x dioxane ring CH 2); 35.91 
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(aliphatic ring CH 2); 34.65 (aliphatic quaternary); 28.56-22.18 (4 x aliphatic ring 
CH2); 17.47 (CH3); m!z (FAB)201 (MH). 
ONIVIRPIOM-91 OR In 
Cyclohexanone (44.50m1, 0.43M) and tris(hydroxymethyl)nitromethane (64.93g, 
0.43M), plus a catalytic amount of TsOH were refluxed in toluene, overnight, using a 
Dean Stark apparatus. After 24 hours, the solution was cooled to room temperature, 
washed with water (2 x 100m1), and the organic layer dried over MgSO 4 . 
Concentration in vacuo gave a cream coloured solid, recrystallization from 
hexane/ether gave the title compound. (42g, 42%); m.p. 99 °C (lit.,6 97-98);(found: 
C,52.19; H,7.54;N,5.65; C 10H 170 5N requires: C,51.96; H,7.36; N, 6.06%); t.l.c. (ethyl 
acetate/hexane, 3:7) Rf 0.57; o m (nujol) 3415 (OH); 1545 (NO2); 6H(CDCI 3 , 
200MHz) 4.36 (2H, d, J 12.56 Hz, equatorial dioxane ring CH 2); 4.09 (2H, d, J 6.33 
Hz, CH20H) 4.07 (211, d, J 12.57 Hz, axial dioxane ring CH 2); 2.09 (IH, t, J 6.38 Hz, 
OH); 1.79-1.40 (1 OH, m, aliphatic ring C11 2); 8C(CDCI 3 , 50MHz) 99.19 (ring 
junction quaternary C); 86.28 (quaternary C); 63.10 (CH20H); 60.19(2 x dioxane 
ring CH2); 32.44-21.93 (5 x aliphatic ring CH 2); mlz (FAB) 232 (MH). 
I3h.w.t ,wj mnin csn'j*inio,t'jflt'l M] 
Fmoc-glycine (1.24g. 4.17mM) was dissolved in DCM (SOml), to this was added 
DCC (0.86g, 4.17mM), and the mixture sonicated for 1 Smins. A solution of 
compound (53) (ig 4.18mM) in DCM was then added together with a tenth of an 
equivalent of DMAP. The resultant mixture was stirred at 5°C for twelve hours. The 
white solid formed (urea) was filtered off and the filtrate washed with Na 2CO3 (2 x 
50m1) and water (2 x SOml). The solution was dried (MgSO 4) then evaporated in 
vacuo to yield the title compound as a white solid (1.83g. 85%): Upon 
recrystallisation from ethyl acetate/hexane, m.p 136-138°C (found: 
C,64.94;H,5.16;N,5.28, C 281-126OgN2 requires: C,64.86;H,5.02;N,5.40%); t.l.c. (ethyl 
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acetate/hexane, 7:3) Rf 0.85, um (nujOl) 3448 (NH); 1751 (ester CO); 1724 
(urethane CU);1555 (NO2);? m (MeUH) 265nm (c 24000 dm3 moi' cal'), 290 
(6100), 300 (7500); 8H(360 MHz, CDCI 3) 7.25-7.76 (13H, m, aromatic); 5.50 (1H, 
s,benzylidene CH); 5.33 (1H, t, amine NH); 4.95 (2H, d, J 12.08 Hz, equatorial ring 
pair 2CH); 4.43 (2H, d, J 6.83 Hz, fi CH2); 4.39 (2H, s, ester CM 2); 4.22 (1H, t, J 6.85 
a CH); 4.07 (2H, d, J 12.46 Hz, axial ring pair 2CM); 3.98 (2H, d, J 5.28 Hz, glycine 
CM2); öc(SO MHz, DMSU) 169.75 (ester CO); 156.73 (Fmoc CO); 143.95, 140.93 
(Fmoc quaternary); 137.33 (benzyl quaternary); 129.34-120.32 (aromatic CH); 
100.61 (benzyl CM); 85.63 (aliphatic ring quaternary); 67.86 (aliphatic ring CH 2); 
66.04 (Fmoc CH2); 63.33 (ester CM 2); 46.76 (Fmoc CH); 42.15 (glycine CH 2); mlz 
FAB) 520 (MH 1 ); HRN4S found 519.176575, C28H2608N2 requires 519.17674. 
The 3-methyl-3-nitro-1 :5-diol ester of 9-fluorenylmethoxycarbonyiglycine (2g, 3.86 
mM) was added to TFA!H20 95/5 (25ml) the mixture was stirred under nitrogen for 
3 hours. The solvent was then removed in vacuo, H20 added, and the white solid 
product re-extracted into ethyl acetate (2 x lOOml). The ethyl acetate was dried with 
MgSO4 and the product absorbed from this solvent onto silica. Wet flash 
chromatography, eluting with ethyl acetate/hexane gave the title compound as a 
white solid, which rapidly becomes a gum on exposure to air. (1.5g, 90%), (Found: 
C,58.77; H,54.90; N,6.61. C21H2208N2 requires C,58.46; H,5.10; N,6.49%); t.l.c. 
(ethyl acetate/hexane, 7:3)Rf 0.4, u max  3411 (OH), 1750 (ester CO), 1703 (urethane 
CO), 1547 (NO2); kmax 265 (c 28000 dm3 mol' cal'), 290 (7100), 300 
(9000);8H(CDCI3, 360MHz) 7.75-7.25 (8H, m, aromatic); 5.46 (1H, t, NH); 4.65 
(2H, s, ester CH 2
); 4.39 (2H, d, J 6.89 b CM); 4.19 (1H, t, J 6.89 a CM); 4.02 (4H, s, 
2CH20H); 3.93 (2H, d, J 5.9 glycine CM2); 6C(DMSO, 50MHz) 156.77 (ester CO); 
169.85 (Fmoc CO); 144.01, 140.96 (Fmoc quaternary); 127.91-120.37 (Fmoc 
aromatic CM); 93.48 (aliphatic quaternary); 66.05 (Fmoc CM2 ); 60.11 (ester CM 2); 
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59.83 (2 x CH20H); 46.76 (Frnoc CH); 42.22 (glycine CI-12); mlz (FAB) 431 (MH), 
HRMS found 431.14561, C21 H22N208  requires 431.14544. 
iiFd 5fl siN4 	JR 	ItOMI 
L. 	WIUl 
N9fluorenylmethoxyCarbOnYlglYCifle (1 .42g, 4.78mM) was dissolved in DCM 
(SOml) to this was added DCC (0.98g, 4.78mM) the mixture was then sonicated for 
15mins. A solution of compound 95 (1g. 4.81mM) in DCM was then added together 
with a tenth of an equivalent of DMAP. The resultant mixture was stirred at 5 °C for 
twelve hours. The white solid formed (urea) was filtered off and the filtrate washed 
with Na2CO3 (2 x 50m1 ) and water (2 x 50m1). The solution was dried (MgSO 4) 
then evaporated in vacuo to yield an oily gum. Wet flash chromatography using an 
ethyl acetate/hexane gradient gave the title compound as a white solid (1 .50g, 64%); 
rn-p 114-117°c (found: C,71.00;H,5.89;N,2.95, C 291-12906N requires 
C,71 .40;H,5.99;N,2.87%); t.1.c.(ethyl acetate/hexane, 4:6)Rf 0.60, u,,(nujol) 
3417(NH), 1721 (ester CO), 1706 (urethane CO); ? m (MeOH) 265nm (c 
27000dm3mol'cm 1 ), 290nm (6800), 300nm (8400);3H(CDC1 3 , 360MHz) 7.8-7.2 
(13H, m, aromatics); 5.54(1H, t, NH); 5.41(1H, s, benzylidene CH); 4.47(21-1, s, ester 
CH2); 4.40(2H, d, J 7.13 Frnoc CR 2); 4.22(1H, t, J 6.87 Fmoc CH); 4.04(2H, d, J 
11.90 equatorial ring pair 2CR); 3.98(2H, d, J 5.73Hzglycine CH 2); 3.65(2H, d. J 
11.89 axial ring pair CH2); 0.78(3H, s, CI -13); ÔC(DMSO, 50MHz) 170.35 (ester CO): 
156.71 (Fmoc CO); 143.89 (Fmoc quaternary); 140.85 (benzyl quaternary); 128.88-
120.26 (aromatic CH); 100.92 (benzilidene CH); 72.36 (dioxane ring CR 2); 66.27 
(Fmoc CH2); 65.93 (ester CH2) 55.03 (aliphatic quaternary); 46.69(Fmoc CH); 42.37 
(glycine CR2); .17.02(CH3); mlz(FAB) 488(MH 4); HRMS found 488.20854 
C29112906N requires 488.20731 
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The 5-hydroxymethyl-5-methyl-2-phenyl-1 :5-dioxane ester of 9-
fluorenylmethoxycarbonyiglycine, compound 96 (2g 4.09mM), was added to 
TFAI1-120 (25m1) and the mixture stirred under nitrogen for three hours. The solvent 
was then removed in vacuo, H20 added and the white solid product re-extracted into 
ethyl acetate (2 x lOOmi). The ethyl acetate was dried with MgSO 4 and the product 
absorbed from this solvent onto silica and then purified by wet flash 
chromatography. Eluting with ethyl acetate/hexane gave the title compound as an 
unstable hydroscopic gum which breaks down to the ordinary glycine compound 
over time. (1.32g. 81%); t.l.c.(ethyl acetate/hexane, 6:4) Rf 0.44; o ma,(gum) 
3424(OH); 297 1(CH); 1785(ester CO); 1707(urethane CO); A.,(MeOH) 265nm(c 
26000dm3mo11  cm'); 290nm(6600); 300nm(8 100); 5H(CDC1 3 , 360MHz); 7.76-
7.25(8H, m, aromatic); 5.25(1H, t, J 5.56Hz, NH); 4.39(2H, s, 3 CH 2); 4.24-4.21(3H, 
s, ester CH2, and obscured t, czCH); 5.98(2H, d, J 5.62Hz, glycine CH 2); 3.38(4H, s, 
CH20H); 0.87(3H, s, CH3); 8C(DMSO, 90MHz); 170.52 (ester CO); 156.78(Fmoc 
CO); 144.05, 140.98 (Fmoc quaternary); 127.84-120.30 (Fmoc aromatic CH); 66.79 
(Fmoc C112 ); 66.03 (ester CH 2); 63.67 (2 x CH20H); 46.86 (Fmoc CH); 42.38 
(glycine CH2); 40.88 (aliphatic quaternary); 21.1 7(CH 3);mlz (FAB) 399 (MH 1), 
HRMS found 399.16553, C 22H25N06 requires:399.16819 
undecane (69) 
To a stirred flask of sodium dried toluene under an inert atmosphere of argon, 
compound 98(1g. 5mM), triphosgene (0.5g. 1.66mM), and DIFA (0.9m1, 5mM) are 
added. After fifteen minutes a white precipitate was formed (DIEA.HCI), the first 
step in the reaction, formation of the chloroformate, can be adjudged to have been 
completed (confirmed by sharp IR peak C=O 1 779cm' in toluene). 
The chioroformate was reacted immediately in situ by the addition of a 
mixture of pentafluorophenol (1.1g. 5.5mM), and DIEA (0.9m1, 5mM), dissolved in 
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the minimum amount of toluene. The reaction was then stirred for a further fifteen 
minutes, (comparative JR indicates loss of sharp peak at 1 779cm', appearance of less 
well defined peak at 1787cmj. The reaction mixture was washed twice with iced 
water, followed by brine solution and dried over MgSO 4. The resultant solvent was 
then evaporated in vacuo to yield a white solid, which on recrystallization from 
hexane/ethyl acetate gave the title compound as large clear crystals. (2.09g, 95%); 
m.p. 121-123 °C (found: C,46.26;H,3.62;N3.17, C 17H 16N07 
requires:C,46.56;H,3 .72;N,3.33%); t.l.c. (ethyl acetate/hexane, 3:7) Rf 0.65; 
u(nujol) 1787 (CO) 1529 (NO 2); 8H(CDCI3 250MHz) 4.85 (2H, s, CH20-); 4.45 
(2H, d, J 12.63Hz equatorial ring pair 2 x CH); 4.12 (211, d, J 12.66Hz axial ring pair 
2 x CH); 1.85-1.42 (bR, m, aliphatic ring CR 2); 8C(CDCI 3, 50MHz) 150.45 (CO); 
100,01 (ring junction quaternary C); 83.15 (aliphatic quaternary C); 68.24 (CH20-); 
60.42 (dioxane ring 2 x CH2); 33.96-22.24 (aliphatic ring S x CH 2); mlz (FAB) 442 
(MH 1), HRMS found: 442.09070; C 1711 1 6N07, requires: 442.09252. 
undecane (78) 
To a stirred flask of sodium dried toluene under an inert atmosphere of argon, 
compound 74 (2.31g. 10mM), triphósgene (0.98g. 3mM), and DIEA (1.7ml, 10mM) 
are added. After fifteen minutes a white precipitate was formed (DIEA.HCI), and the 
first step in the reaction, formation of the chioroformate can be adjudged to have 
been completed (confirmed by sharp JR peak C0 1 779cnf' in toluene). 
The chloroformate was reacted immediately in situ by the addition of a 
mixture of pentaflurophenol (1.84g. 10mM), and DIEA (1 .7ml, 10mM), dissolved in 
the minimum amount of toluene. The reaction was stirred for a further fifteen 
minutes before washing twice with iced water, followed by brine solution and dried 
over MgSO4. The resultant solvent was then evaporated in vacuo to yield a white 
solid, which on recrystallization from hexane/ethyl acetate gave the title compound 
as large clear crystals. (3.86g. 95%); m.p. 101-102 °C (found: C,52.68;H,4.63, 
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C 18H 1905F 5  requires: C,52.48;H,4.77%); t.l.c. (ethyl acetate/hexane, 1:1) Rf 0.76; 
u(nujol) 1777 (CO); 6H(CDCI 3 250MHz) 4.45 (2H, s, CH20-); 3.67 (411, s, 2 x 
dioxane ring CH2); 1.88-1.24 (101-1, m, aliphatic ring CH 2); 0.89(311,5, CH3); 
3C(CDCI 3, 50MHz) 151.28 (CO); 98.26 (ring junction quaternary C); 73.05 (CH20-
); 64.96 (2 x dioxane ring CH 2); 36.45-22.30 (5 x aliphatic ring CH 2); 35.01 
(aliphatic quaternary) 17.19 (CH 3); mlz (FAB) 411 (MH), HRMS found: 
411.12395; C 131-1 1905 F5 , requires: 411.12309. 
To a stirred flask of DCM (lOOm!) under an inert atmosphere of argon, 5-
hydroxymethyl-5-nitro-2-phenyl-1 :3-dioxane (2g, 8.36mM) was added together with 
p-nitrophenylchlorofonnate (1.885g, 9.35mM) and pyridine (1 .7m1, 21 mM). The 
mixture was stirred for 4 days and then washed with water (2 x 50m1) and dried over 
MgSO4. The resultant solvent was evaporated in vacuo to give a white solid, 
recrystallization from ethyl acetate/hexane gave the title compound as a crystalline 
white solid. (1 .98g, 59%);m.p. 156-160 °C (found:C,53.60;H,4.40;N,6.84; 
C 18H 16N209 requires: C,53.46;H,3.96;N,6.93%); t.1.c. (ethyl acetate/hexane, 1:1) Rf 
0.50; u(nujol) 1781 (CO) 1571 (NO 2); 8H(CDC1 3,25OMHz) 8.34 (211, d, J 
9.17Hz, 2 x NO2 proximity aromatic CH); 7.60 (2H, d, J 9.15Hz, 2 x 0 proximity 
aromatic CH); 7,37 (51-1, s, aromatic CH); 5.71 (111, s, benzylidene CH); 4.89 (2H, d, 
J 12.77Hz, 2 x equatorial dioxane ring CH); 4.66 (211, s, ester CH 20-) 4.44 (211, d, J 
12.92Hz, 2 x axial dioxane ring CH); 8C(CDCI 3, 50MHz) 164.07 (CO); 155.02, 
145.46, 137.19 (aromatic quaternary); 129.25-122.59(5 aromatic CH); 100.62 
(benzylidene CH); 85.22 (aliphatic quaternary); 67.72 (2 x dioxane ring CH 2); 67.32 
(ester CH2); m/z (FAB) 405 (MH 1), HRMS found:405.09463; C 18H 16N209 , 
requires:405 .0934 1. 
IIPW 
To a stirred flask of DCM (lOOmI) compound 67 (1 g, 2.47mM) was added together 
with benzylamine (0.26g, 2.47mM) and DIEA (0.32g. 2.47mM). A strong yellow 
colouration was observed as p-nitrophenol is liberated. The reaction mixture was left 
overnight and then washed with citric acid (SOml), water (2 x 50m1) and dried over 
MgSO4 . The solvent was then removed in vacuo to leave an oil, wet flash 
chromatography eluting with ethyl acetate/hexane gave the title product as a white 
crystalline solid.(0.919g, 45%) m.p.140-142 °C (found: C,61.40;H,5.59;N,7.40; 
C 1 H2006N2  requires: C,61.26;H,5.37;N,7.52%) t.l.c. (ethyl acetate/hexane, 7:3) Rf 
0.72; u m.(KBr) 3276 (NH) 1717(CO) 1553 (NO 2); 8H(DMSO, 360MHz) 8.01 (1H, 
t, J 6.07Hz, NH); 7.38-7.22 (10H, m, aromatic CH); 5.67 (1H, s, benzylidene CH); 
4.79 (2H, d, J 12.87Hz, 2 x equatorial ring CH); 4.37 (2H, s, ester CH 2); 4.35 (2H, d, 
J 12.37Hz, 2 x axial ring CH); 4.18 (2H, d, J 6.12Hz, CH2NH); SC(DMSO, 90MHz) 
155.3 (urethane CO); 139.37, 137.29 (aromatic quaternary); 129.23-126.15 (aromatic 
CH); 100.545 (benzylidiene CH); 86.06 (aliphatic quaternary); 67.95 (2 x dioxane 
ring CH2); 63.12 (ester CH 2); 43.96 (CH2NH); mlz (FAB) 373 (MH), HRMS 
found:373. 14240; C 19H2006N2, requires:373. 13996. 
Compound 97 (0.50g, 1.34mM) was added to a mixture of 9:1 TFAIH20 (25m1) and 
the mixture stirred under an inert atmosphere of nitrogen for 3 hours. The TFA was 
then removed in vacuo, water added, and the white solid produced re-extracted with 
ethyl acetate (2 x SOml), The ethyl acetate was dried with MgSO 4 and then absorbed 
on to silica. Wet flash chromatography eluting with ethyl acetate/hexane gave the 
title compound as a white solid. (0.31g, 82%); (found: C,50.63;H,6.04;N,9.58, 
C 12H 16N206, requires: C,50.68;H,5.67;N,9.58%); t.l.c. (ethyl acetate/hexane, 7:3) Rf 
0.45; um (KBr) 3310 (OH) 1698 (CO) 1562 (NO 2); ÔH( DMSO, 250MHz) 7.35-7.20 
(5H, m, aromatic CH); 5.54 (1 H, t, J 5.843 NH); 4.57 (2H, s, ester CH 20-); 4.31 (2H, 
d, J 5.96 CH2NH-); 3.96 (4H, s, 2 x CH20H); SC(DMSO, 90 MHz) 155.78 (CO); 
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139.579 (aromatic quaternary); 128.401, 127.218, 126.977 (aromatic CH); 93.44 
(aliphatic quaternary); 60.36 (ester CH 20-); 59.47 (C1-1 20F1); 43.94 (CH 2NH-); mu 
(FAB) 285 (MH+), HRMS found: 285.10863; C 12H 16N206, requires: 285.10866. 
4-Formyiphenoxyacetic acid (4.80g. 26.6mM) was dissolved in DCM (200m1) and to 
this was added DCC (5.479g 26.6mM) the mixture was sonicated for 15 minutes. A 
solution of pentachlorophenol (7.25g, 27.2mM) in DCM was then added together 
with DMAP (1mM, catalytic amount). The resultant mixture was stirred at 5 °C for 
twelve hours. The white solid formed (urea) was filtered off and the resultant solvent 
washed with water, dried with MgSO4 and absorbed onto silica. Dry flash 
chromatography eluting with ether/hexane gave the title compound as a white 
crystalline solid. (8.5g. 75%) m.p. 112-115°C (found: C,42.13;H,1.76; C 15H704C1 5 
requires: C,42.01;H,1.65%); t1c. (ethyl acetate/hexane, 3:7) Rf 0.71, u(nujol) 
1783 (ester CO); 1677 (aldehyde CO); 8H(CDCI 3, 200MHz) 9.91 (1H, s, aldehyde 
CH); 7.90 (211, d, J 8.90, aromatic CH); 9.37 (21-1, d, J 8.82, aromatic CH); 5.10 (21-1, 
s, C112); SC(DMSO, 50MHz) 191.44 (aldehyde CH); 170.19 (CO); 162.77, 158.32, 
(aromatic chioro quaternary); 150.46 (aromatic quaternary); 127.62, 114.15 (aromatic 
CH); 130.10, 121.46 (aromatic quaternary); 66.36 (CH 2); mlz(FAB) 428 (MH+), 
HRMS found: 428.88519; C 1511 1704C 15, requires: 428.88357. 
(42) 
To a stirred 500m1 flask of sodium dried toluene (250m1), compound 40 was added 
(8g, 18.69mM) together with tris(hydroxy)nitromethane (4.25g. 28nilvI) and a 
catalytic amount of TsOH (100mg). The resultant mixture was then refluxed under 
Dean and Stark conditions for 24hrs. The toluene was removed in vacua and the 
resultant gum re-dissolved in ethyl acetate. This solution was then washed with brine 
(2 x lOOml), water (2 x lOOm!) and dried with  MgSO4. The ethyl acetate was 
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removed in vacuo to give a yellow solid, recrystallisation of this solid from ethyl 
acetate/hexane gave the title compound as white crystals. (9g. 85%); m.p. 156-162 °C 
(found:C,40.69;H,2.27;N,2.40; C 191-1 14N08 C1 5 requires: C,40.64;H,2.49;N,2.49%); 
t.l.c. (ethyl acetate/hexane, 7:3) Rf 0.43; o m (nujol) 3552 (OH); 1801 (CO); 1544 
(NO2), 8H(CDC1 3, 250MHz) 7.26 (21-1, d, J 8.81,2 x aromatic CH); 6.89 (21-1, d, J 
8.85, 2 x aromatic CH); 5.57 (1H, s, ben.zylidene CH); 4.76 (21-1, d, J 12.75, dioxane 
ring equatorial CH's); 4.66 (21-1, s, ester CH 20); 4.20 (2H, d, .112.82, dioxane ring 
axial CH's); 3.69 (2H, s, CH20H); 8C(CDCI 3 , 60MHz) 170.18 (CO); 158.23, 
150.36, 130.44, 121.48, (aromatic quaternary); 127.47, 114.04 (aromatic CH); 
100.41 (benzylidene CH); 88.13 (aliphatic quaternary); 68.22 (aliphatic ring CH 2); 
64.50 (ester CH20-); 62.40 ( CH 20H); mlz (FAB) 562 (MH-f), HRMS found 
561.92111, C 191-1 14NO805 requires 561.92107 
To a stirred flask of DCM (lOOmI) Fmoc-glycine (0.5g. 1.68mM) was added together 
with DCC (0.34g. 1.68mM) the mixture was sonicated for 15 mins and then cooled 
in an acetone dry ice bath for 30mins. Compound 42 (1 g, 1.78mM) was then added 
and allowed to dissolve. To the resultant solution a catalytic amount of DMAP 
(10mg) was added (care should be taken as the addition of too much DMAP results 
in the loss of the PCP group and an impure product) and the mixture transferred from 
the acetone bath to the cold room. The mixture was stirred for a further 3 hours and 
then worked up. The white solid was filtered off and the solvent washed with water 
(2 x SOml), and dried with MgSO4. Removal of the solvent in vacuo yields a gum, 
trituration of this gum with hexane provides a white solid which was pure enough for 
attachment to a resin. Improved purity was obtained by wet flash chromatography: 
Chromatography of the above solid eluting with ethyl acetate/hexane gave the title 
compound (1.28g. 90%); m.p.178-182°C (found: C,51.69;H,3.52;N,3.23, 
C361-1270 1 1N2C15  requires: C,5 1 .42;H,3 .21 ;N,3 .23%); t.l.c. (ethyl acetate/hexane, 6:4) 
Rf 0.48; um (KBr)3324 (NH); 2928 (CH); 1762 broad (CO. glycine & Pi'j ester); 
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1726 (CO. urethane); 1553 (NO 2); 6H(DMSO, 360MHZ) 7.88-6.87(1 1H, m, 
aromatic CH); 5.59 (111, s, benzylidene CH); 4.77 (21-1, d, J 12.41 dioxane ring 
equatorial CH's); 4.66 (21-1, s, -OCH2CO); 4.46 (2H, s, ester CH20-); 4.34-4.27 (5H, 
m, dioxane ring axial CH's, (x CH, 0 CR2 ); 3.80 (2H, d, J 5.77Hz glycine CH 2); 
SC(DMSO, 90MHz) 169.92 (CO, PCP); 169.38 (CO. ester); 156.41 (CO, urethane); 
158.09, 156.41 (aromatic chloro quaternary); 143.63, 140.61 (Fmoc quaternary); 
130.01, 129.92, 121.29 (benzyl quaternary); 127.53, 127.26, 126.98, 125.02 
(aromatic Fmoc CH); 119.99, 113.86 (benzyl CH); 100.19 (benzylidene CH); 85.25 
(aliphatic quaternary); 67.53 (dioxane ring CH 2); 65.75 (Fmoc CI-1 2); 64.30, 63.03 
(ester CR2); 46.46 (Fmoc CH); 41.85 (glycine CH 2); m/z (FAB) 841 (MW); FIRMS 
found: 841.01064; C36H270 11N2C1 5 , requires: 841.01061. 
(45) 
Boc-Glu(OBzl)OCH 2-PAM resin (0.5mM) was sonicated in lOml of 9:1, TFA4I 20 
for 20 mins. The resin was then washed with DMF, DCM, and diethyl ether. A 
Kaiser test was performed to check the removal of the Boc protecting group. The 
above resin (500mg, 0.64niMIg substitution) was then sonicated in DMF with 
compound 44(1g. 1.18mM) and TEA (lOOjil, 0.72mM) for 12 hours. The resin was 
then filtered and washed with DMF, DCM and ether (loading 78%, weigh 625mg). 
The above peptide was then synthesised using this functionalized linker. All side 
chains were protected as described previously and all residues were coupled using 
standard double coupling cycles. The first two amino acids were introduced as a 
dipeptide to avoid the problem of diketopiperazine formation. At the completion of 
the assembly stage, the resin bound peptide was sequentially washed with DMF, 
DCM, diethyl ether and dried to give 564mg of product. The peptide was then 
cleaved from a 176mg batch of resin by stirring with 9:1, TFAIH 20 for 2 hours at 
room temperature. The resin was then removed by filtration and washed with TFA. 
Evaporation of the filtrate and trituration with diethyl ether yielded the crude peptide 
which was isolated by filtration, before being dissolved in aqueous acetic acid (10%) 
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and lyophilised to yield 25mg of white solid. The peptide was purified using semi-
preparative HPLC (Aquapore C18, 250 x 10mm, 10MM, A=H 20, B=CH3CN, 0.1% 
TFA; 5m1/min. 10% B for 2 mins then 10-90% B over 30 mins. X=2 l4nm). The 
main peak eluting at 51% B was isolated and lyophilised to give 10mg of the title 
compound. Analytical HPLC (C18 Aquapore Rp300 220 x 4.6mm ,7sm, A=H 20, 
B=CH3CN, 0.1% TFA; lml/min. 10-90%B over 30 mm. X=214nm) Rt=14.2mins, 
38%B; amino acid analysis: Asp 1 1.18, G1y 1 1.17, Ala 1 1.12, lIe 1 1.00, Leu2 1.85, 
Phe 1 1.08; mlz(FAB) 881 (MH 1), HRMS found 88 1.46049, C401-165N80 14 requires 
881.46202. 
N-benzyloxycarbonylphenylalanine (D/L) (I g, 3.34mM) was dissolved in DCM 
(50m!) to this was added DCC (0.688g, 3.34mM) the mixture was sonicated for 
1 Smins. A solution of compound 53 (1g, 4.18mM) in DCM was then added together 
with a catalytic amount of DMAP (0.036g, 0.3mM). The resultant mixture was 
stirred at 5 °C for 1 hour and then at room temperature for a further 2 hours. The 
white solid formed (urea) was filtered off and the filtrate washed with Na 2CO3 (2 x 
SGml) and water (2 x 50m1). The solution was dried over MgSO 4 then evaporated in 
vacuo to leave a gum. Purification by wet flash chromatography eluting with ethyl 
acetate/hexane gave the title compound as oily gum which on drying became a foam. 
(1.47g. 85%). (Found: C,64.38;H,5.44;N,5.18; C281-123N208 requires: 
C,64.55;H,5.37;N,5.37%); t1c. (ethyl acetate/hexane, 7:3) Rf 0.6; u(gum) 3332 
(NH); 3032 (aromatic CH); 2968 (aliphatic CH); 1752 (ester CO); 1712 (urethane 
CO); 1554cm' (NO 2); SH(DMSO, 360MHz) 7.92 (11-1, d, J 7.85Hz NH); 7.38-7.23 
(15H, m, aromatic CH); 5.66(1,s, benzylidene CH); 5.00 (21-1, d, J 3.77 benzyl 
CH2); 4.45 (21-1, s, ester CH 2); 4.824.70 (21-1, d of d, J 12.80 diasteriomeric dioxane 
ring axial CH2's ); 4.45 (21-1, s, ester CI-12) 4.33-4.25 (31-1, m, diasteriomeric dioxane 
ring equatorial CI-12 's and a CH); 3.03-2.85 (2H, m, j3 CH2); ÔC(DMSO, 90MHz) 
171.158 (ester CO); 156.17 (urethane CO); 137.32, 137.28, 136.89 (aromatic 
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quaternary); 129.31-126.82 (aromatic CH); 100.58 (benzylidene CH); 85.56 
(aliphatic quaternary); 67.83, 67.74 (dioxane ring CH 2); 65.77 (benzylmethoxy CH 2 ); 
63.47 (ester CH 2); 55.58 (a CH); 36.25 (J3 CH 2); mlz (FAB) 519 (MH), HRMS 
found 521.19205, C 23 1-128N208 requires 521.19239. 
Compound 61 (0.5g, 0.96mM) was added to TFAlwater 95:5 (5m!) the mixture was 
stirred under nitrogen for 3 hours. The solvent was then removed in vacuo, water 
added, and the white solid product re-extracted into ethyl acetate (2 x 50m). The 
ethyl acetate was dried with MgSO 4 and the product absorbed from this solvent onto 
silica and then purified by wet flash chromatography. Fluting with ethyl 
acetate/hexane gave the title compound as a yellow oil. (0.35g, 84%); [cz] 0=0.0° , 
c=1.0 in MeOH; (found: C,57.73;H,6.10;N,6.40, C 21 1-125N208 requires: 
C,58.17;H,5.81;N,6.46%); t.l.c. (ethyl acetate/hexane, 7:3) Rf 0.5, U m (oil) 3409 
(OH); 3035 (aromatic CH); 2940 (aliphatic CH); 1745 (ester CO); 1694 (urethane 
CO); 1551 (NO2); SH(DMSO, 360MHz) 7.82 (11-1, d, J 8.43 NH); 7.37-7.16 (10H, m, 
aromatic CH); 5.47 (21-1, t, J 5.45 OH); 4.96 (21-1, s, benzyl CR 2); 4.55-4.43 (21-1, d of 
d, J 11.62Hz, diasteriotopic ester CH 2); 4.33 (1 H, m, a CH); 3.84-3.69 (41-1, 
m,CH20H); 3.16-3.03 (21-1, m, CH2);  5C(CDCI3,) 171.10 (ester CO); 156.22 
(urethane CO); 137.50, 136.92 (aromatic quaternary); 129.162-126.140 (aromatic 
CH); 93.39 (aliphatic CH); 65.60 (benzyl CH 2); 60.28 (ester CH 2) 59.87, 59.81 
(CH20H); 55.49 (aCH); 36.36 (CH 2); (FAB) 453 (MNa) HRMS found: 
455.14297; C21 1-125N2O8Na, requires: 455.14307. 
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Benzylmethoxycarbonylphenylalanine (D/L) (0.5g, 1.67mM) is dissolved in DCM, 
to this DCC (0.344g, 1.67mM) is added and the mixture sonicated for 1 Smins. 
Piperidine (0.1 65ml, 1.67mM) was then added and the mixture stirred for a further 2 
hours. The mixture was then washed with brine (2 x 25m1) and water (2 x 25ml) and 
dried over MgSO4 . The DCM was removed in vacuo and a white solid triturated out 
with hexane, recrystallisation from ethyl acetate/hexane gave the title compound as 
clear crystals. m.p.225-229 °C; (Found: C,72.13;H,7.88;N,7.86, C 28H26N203 
requires:C,72.13;H,7.70;N,7.6%); t.1.c. (ethyl acetate/hexane 7:3) Rf 0.64, 
um (KBr) 3242 (NH); 3030 (aromatic CH); 2927 (aliphatic CH); 1706 (urethane 
CO); 1633 (amide CO); SH(DMSO, 360MHz) 7.64 (11-1, d, J 8.39Hz, NH); 7.35-
7.19 (1 OH, m, aromatic CH); 4.97 (21-1, d, J 3.63 Hz, benzyl CH 2); 4.67 (1H, d of d, J 
8.146, 8.078 (tCH); 2.93-2.49 (21-1, m, 13CH2); ÔC(DMSO, 60MHz); 169.19 (amide 
CO); 155.72 (urethane CO); 137.72,137.13 (aromatic quaternary); 129.42-126.43 
(aromatic CH); 65.34 (benzyl CH2); 51.83 (ctCH); 45.98,42.56 (aliphatic ring 
NCH2-); 37.68 (CH2); 25.83,25.29,24.02 (aliphatic ring CH2); mlz (FAB) 367 
(MH+); J{lJvf S found 367.19994, C 28H26N203 requires: 367.20217 
Aminoundecanoic acid (2g. 9.9mM) was dissolved in DMF/TEA, 10:1 (50m1) to this 
mixture di-t-butyl dicarbonate (4.365g. 20mM) was added. The mixture was heated 
to 80°C and stirred until all the white slurry has dissolved and the solution become 
clear. The DMF was partially removed in vacuo and the mixture poured into ice cold 
water acidified to pH 2 with citric acid. The solid was then re-extracted using ethyl 
acetate and the resultant solution dried over MgSO4. The solvent was removed in 
vacuo to give a white solid, recrystallisation from ether/hexane gave the title 
compound as white crystals. (2.5g. 83.5%) m.p.63-65 °C 
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(found:C,63 .5 5;H, 1 0.45;N,4.55, C 16H31N04 requires: C,63.78;H,1 0.29;N,4.64%); 
t.l.c. (ethyl acetate/hexane, 1:1)Rf 0.37; Dma,, (nujol) 3365 (NH); 3000-2500 (broad 
acid OH); 1684 (urethane & acid CO); SH( CDCI 3 , 250MHz); 2.89 SC( DMSO, 
60MHz); 174.51 (acid CO); 155.64 (urethane CO); 77.31 (aliphatic quaternary); 
33.74, 29.55, 29.04, 28.92, 28.81, 28.64 (CH 2); 28.32 (CH 3); 26.34, 24.57 (CH 2); 
mlz (FAB) 302 (MH+), HRMS found: 302.23384; C 161-1 31N04 requires: 302.233 13. 
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Compound 70, (0.692g, 2.29mM) was added to DCM (50m1) together with DCC 
(0.473g. 2.29mM) and the mixture was sonicated for 15 mins. A solution of 9-
aminofluorene.HC1 (0.5g. 2.29mM) in DCM was then added together with TEA 
(0.35m1, 2.5 1mM) and the mixture stirred for 8 hours. The white solid (urea) was 
filtered off and the filtrate washed with 5% aqueous citric acid (2 x 25m1), water (2 x 
25m1), and dried over MgSO4 . The solvent was removed in vacuo and a white solid 
formed on tituration with ethyl acetate/hexane, recrystallization from ethyl acetate 
gave the title compound as fine white crystals. (0.7g, 77%); m.p. 136 °C (found: 
C,75.04;H8.96;N,6.37; C 29H40N203 requires: C,74.96;H,8.96;N,6.03%); t.l.c.(ethyl 
acetate/hexane, 1:1) Rf 0.54; o(nujol) 3354 (urethane NH); 3311 (amide NH); 
1675 (urethane CO); 1640 (amide CO); X m ,,(MeOH); 269 (e 73000 dm  mor' cm'); 
5H(CDCI3, 200MHz); 7.65-7.21 (8H, m, aromatic CH); 6.21 (1H, d, J 8.91Hz 
fluorene NH); 5.93 (1H, d, J 8.75Hz fluorene CH); 6.12 (2H, q, 6.52Hz, -NHCH2-); 
2.24 (1H, t, 7.2FIz, -NHCHr); 1.39 (8H, s, CH2); 1.24 (91-1, s, CH 3); 8C(CDCI3 , 
50MHz); 173.79 (amide CO); 155.82 (urethane CO); 144.33, 140.38 (aromatic 
quaternary); 128.43, 127.54, 124.90, 1 19.77(aromatic CH); 78.88 (aliphatic 
quaternary); 54.43 (fluorene CH); 40.43, 36.67, 29.88, 29.25, 29.20, 29.07 (CH 2); 




Compound 71, (0.5g, 1.07mM) was added to 20m1 of TFA/H 20, 9:1 and stirred for 
four hours under nitrogen. The TFA was then partially removed in vacuo and the 
concentrated mix pored into 5% sodium bicarbonate. The product was re-extracted 
with ethyl acetate, washed with water, and dried over MgSO 4. Removal of the 
solvent in vacuo gave the product as a very sticky gum/oil. HPLC (Cl 8 Vydac 250 x 
4.6 x 5jxm), A=H20, B=CH3 CN, 0.1% TFA; 5m1/min. 10% B for 2 mins then 10-
90% B over 30 mins; %=214nm); Rt=22.4 mins, 65%B); u(nujol) 3271 (NH2); 
1675 (amide CO); ?.mn(MeOH); 269 (c 81000 dm 3mor' cm'); H(DMSO, 
250MHz); 8.40 (1H, d, J 8.40Hz, NH); 7.85-7.28 (aromatic CH); 6.04 (11-1, d, J 
8.35Hz, fluorene CH); 2.78 (21-1, m, CH2NH 2); 2.19 (2H, t, J 7.2, CH2NH2); 
SC(DMSO, 60MHz); 173.01 (CO); 145.06, 140.11 (aromatic quaternary); 128.39, 
127.64, 124.79, 120.19, (aromatic CH); 54.07 (flourene CH); 38.91, 35.36, 28.84, 
28.62, 27.06,25.86,25,51 (CH2); mlz(FAB) 365 (MH+); HRMS found: 365.25822, 
C24H33N20 requires: 365.25929 
FiLI.t.)(IWi  Fro MURIiiI1I!Itt&)] 
To a stirred flask of DMF (SOml) compound 67, (0.655g. 1.4mM) is added together 
with compound 72,(0.555g, 1.37mM) and TEA, (0.155g,1.54m1v1) the reaction 
mixture is stirred for a further twelve hours (note strong yellow colour indicates 
displacement of p-nitrophenol). The solvent was then removed in vacuo to give a 
sticky gum, this gum was re-dissolved in ethyl acetate, and then washed with 5% 
citric acid (SOml), water (2 x SOml) and dried over MgSO 4 before being absorbed on 
to wet flash silica. Elution with ethyl acetate/hexane gave the title compound. 
(0.41g. 48%). m.p.100-104 °C (found: C,68.47;H,6.83;N,6.79; C 36H43N307 requires: 
C,68.64;H,6.83;N,6.67; t.l.c. (ethyl acetate/hexane 1:1) RfO.5l; u m (nujol) 3325 (b, 
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NH); 1712 (CO. urethane); 1630 (CO, amide); 1559 (NO 2); Xmax(Me01) 269 (c 
74000 dm3 moU 1 cmj; 8C(CDC13, 360MHz) 7.69-7.25 (13H, aromatic CH); 6.23 
(1H, d, J 8.89Hz, fluorenyl NH); 5.77 (1H, d, J 8.77Hz, fluorenyl CH); 5.49 (1H, s, 
benzylidene CH); 5.01 (21-1, d, J 12.95Hz, 2 x equatorial ring CH 2); 4.23 (21-1, s, 
carbamate CH 2); 4.08 (2H, d, J 12.85Hz, 2 x axial ring CH 2); 3.12 (21-1, q, J 6.42Hz, - 
CH2CH2NH-); 2.25 (21-1, t, J 7.63Hz, -COCH2CH2-); 1.27 (81-1, bs, CH 2); 
8C(CDCI3 , 90MHz); 173.92 (amide CO); 154.69 (urethane CO); 144.28, 140.45, 
(fluorenyl quaternary); 136.65 (aromatic quaternary); 101.82 (benzylidene CH); 
86.74 (aliphatic quaternary); 68.6 (dioxane ring CH 2); 63.56 (carbamate CH 2); 54.53 
(fluorenyl CH); 41.13-25.67 (CH 2); mlz (FAB) 631 (MH4), HRMS found: 
630.31636; C 36H43N307; requires: 630.31793. 
To a flask of TFA/1-1 20, (9:1), (1 Oml), under an inert atmosphere of nitrogen 
compound 73 (1g, 1.58mM) was added. The mixture was stirred for three hours, the 
TFA was then removed in vacuo and water added, the cloudy white product was then 
extracted into ethyl acetate (2 x 50m1). The ethyl acetate was dried with MgSO 4 and 
the product absorbed from this solvent onto silica and then purified via wet flash 
chromatography. Elution with ethyl acetate/hexane gave the title compound as a 
gum. (0.78g. 92%); HPLC (C18 Vydac 250 x 4.6 x Sjsm), k=H 20, BCH3CN, 0.1% 
TFA; imi/min. 10% B for 2 mins then 10-90% B over 30 mins; ?=300nm; Rt25.34 
mins, 72.24%B); u m (KBr) 3280 b,(UH); 2924 (CH); 1688 (urethane); 1637 
(amide); 1548 (NO 2); X(MeOH); 269 (e 76000 din. 3mof' cm-1 ; SH(DMSU, 
360MHz) 8.38 (11-1, d, J 8.53Hz, fluorenyl NH); 7.85-7.21 (8H, m, aromatic CH); 
6.01 (11-1, d, J 8.63Hz, fluorenyl CH); 4.32 (21-1, s, ester CH 2); 3.78 (41-1, s, CH20H); 
2.95 (21-1, q, J 6.32Hz, -CH2CH2NH-); 2.19 (21-1, t, J 7.1Hz, -COCH 2-); 1.27-1.24 
(81-1, bs, undecane CH 21 s); oC(DMSO, 90MHz); 173.42 (amide CO); 155.52 
(urethane CO); 145.09,140.25 (aromatic quaternary); 128.45,127.72,124.85,120.25 
(aromatic CH); 93.43 (aliphatic CH); 60.16 (ester CH); 59.40 (CH 20H); 40.42 (- 
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CH2CH2NH-); 35.40 (-COCH2CH2-); 29.42-25.57 (-CH 2-); mlz (FAB) 542 (MH 4); 
HRMS found: 542.28508, C29H39N307 requires: 542.28663. 
t 
JI - 
To a stirred solution of dioxanefH 20 (1:1, 50m1), at 0 °C Fmoc lysine (0.5g, 
1.357mM) was added together with compound 69 (0.9, 1.587mM) and TEA 
(0.379ml, 2.714mM). The reaction mixture was then allowed to warm to room 
temperature and stirred over night. The reaction mixture is then concentrated in 
vacuo and the residue dissolved in ethyl acetate. The ethyl acetate is washed with 
brine (2 x 50m1) and water (2 x 50m1) before being dried over MgSO 4 The product 
was then absorbed from the dry solvent onto wet flash silica, elution using 
DCM!MeOH (9:1) gave the title compound as a white solid. (0.68g, 8 1%); [a]D= 
+12°, c=1.0 in MeOH; m.p.172°C; (found: C,61.1OH,6.63N,6.41 C 321-1390 10N3 ; 
requires: C61.40,H6.30,N6.71); t.1.c.(DCMIMeOH, 9:1) Rf 0.30; u m (KBr) 3408 (b, 
NH); 2937 (CH); 1708 (CO); 1552 (NO 2); Xmax(Me01) 265nm (s 19000 dm 3 mol' 
cm'), 290 (4800), 300 (5700); 6H(DMSO, 250MHz); 7.90-7.30 (81-1, m, aromatic 
CH); 4.39-4.33 (6H, bm, 2 x equatorial dioxane ring CH, carbamate CH 2, Fmoc 
CH2); 4.23-4.12 (4H, bm, 2 x axial dioxane ring CH 2 , (X  CH, Fmoc CH); 2.91 (21-1, 
bs, -NHCH2-); 1.84-1.23 (16H, bm, CH2); oC(DMSO, 60MHz); 173.37, (CO, acid); 
155.79, 155.01 (CO, urethane); 143.96,140.84 (Fmoc quaternary); 
129.06,127.42,121.52,120.17 (Fmoc CH); 98.65 (aliphatic ring junction quaternary); 
85.64 (aliphatic quaternary); 65.45 (Fmoc CH 2); 63.24 (ester CH 2); 60.50 (dioxane 
ring CH2); 46.89 (Fmoc CH); 38.60, 28.23, 25.03, 22.20 (f3CH 2 + ring CH2); 30.82 





To a stirred solution of dioxanelH 20 (1:1, SOml) at 0°C Fmoc lysine (1 g, 2.714mM) 
was added together with compound 78 (1.3g. 3.174mM) and TEA (0.758m1, 
5.428mM). The reaction mixture was allowed to warm to room temperature and 
stirred overnight. The reaction mixture was then concentrated in vacuo and the 
residue dissolved in ethyl acetate. The ethyl acetate was washed with brine (2 x 
SOml) and water (2 x 50ml) before being dried over MgSO 4 The product was then 
absorbed from the thy solvent on to wet flash silica, elution using DCMIMeOH (9:1) 
gave the title compound as a white foam. (1.1 2g, 70%); [ct]D=24° , c= 1.0 in MeOH; 
(found: C,66.53;H,7.07;N,4.76; C 33 1-143N208 requires: C,66.60;H,7.07;N,4.76); 
t.l.c.(dichloromethane/methanol 9:1) Rf 0.32; o(nujo1) 3313 (NH); 1701 (b, CO); 
max(Me0H) 265nm (c 22000 din  mo1' cm'), 290 (6000), 300 (7300); ÔH(DMSO, 
360MHz); 7.88-7.30 (81-1, m, aromatic CH); 4.28-4.19 (31 -1, m, Fmoc CR2 & (X CH); 
3.93 (2H, s, ester CI-1 2); 3.53 (41-1, d of d, J 7.57Hz, equatorial & axial dioxane ring 
CH); 2.96 (21-1, q, .16.04Hz, -NHCH); 1.73-1.24 (16H, m, CR 2); 0.77 (3H, s, CH 3 ); 
SH(DMSO, 360MHz); 174.27 (acid CO); 156.57, 156.28 (urethane CO); 144.02, 
143.95 (aromatic quaternary); 127.78, 127.21, 125.43, 120.22 (aromatic CH); 97.36 
(aliphatic quaternary, ring bridge carbon); 66.51 (2 x dioxane ring CI-1 2); 64.65 
(Fmoc CR2); 59.91 (carbamate CR 2); 53.37 (aCR); 46.83 (Fmoc CH); 41.70-22.28 
(CR2); 33.61 (aliphatic quaternary C); 17.57 (CR 3); mlz (FAB) 595 (MI-C); RRMS 
found 595.30170; C 33 1-143N208 requires:595.30194 
To a stirred flask of DMF (SOml) compound 72,(0.55g, 1.51mM) was added 
together with compound 78,(0.62g, 1.51mM) and TEA, (0.30, 3.00mM) the reaction 
mixture was stirred for a further twelve hours. The solvent was then removed in 
vacuo to give a sticky gum, this was re-dissolved in ethyl acetate, the ethyl acetate 
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was then washed with 5% citric acid (50m1), water (2 x 50m1), and dried over MgSO 4 
before being absorbed on to wet flash silica. Elution with ethyl acetate/hexane gave 
the title compound as a white solid. (0.70g. 78%) m.p. 90-94 °C; (found: 
C,72.93 ;H,8.64;N,4.48; C 361-150N205  requires: C,73.20;H,8.47;N,4.75); t.l.c.(ethyl 
acetate/hexane)RfO.53;U max(flUjOl) 3276 (NH); 1695 (CO urethane); 1639 (CO 
amide); ?.m (MeOH); 269 (c 79000 din 3moF'cm'); 6H (DMSO, 360MHz) 8.4 (1H, 
d, J 8.42Hz NH); 7.85-7.29 (81-1, m, aromatic CH); 6.04 (11-1, d, J 8.33Hz CH); 3.93 
(211, s, ester CH 2); 3.58 (2H, d, J 11.43 Hz, 2 x equatorial dioxane ring CH); 3.52 
(2H, d, J 11.56Hz, 2 x axial dioxane ring CH ); 2.96 (2H, q, 6.29Hz ,CH2CH2NH-); 
2.21 (21-1, t, 7.26Hz, -COCH2CH2-); 1.75- 1.03 (18H, m, CH2); (31-1, s, CH3 ) 
SC(DMSO, 90MHz); 173.31 (amide CO); 156.47 (urethane CO); 145.09, 140.121, 
(fluorenyl quaternary); 128.38, 127.65, 124.82, 124.82, 120.19 (fluorenyl CH); 97.28 
(aliphatic quaternary, ring junction C); 66.08 (carbamate CH 2); 64.58 (dioxane ring 
CH2); 54.04 (fluorenyl CH); 40.29-22.17 (CH 2); 33.57 (aliphatic quaternary C);17.54 
(CH3); m/z (FAB) 591 (MR); HRIvIS found: 591.38071; C 36H50N205 requires: 
591.37980. 
To a flask of TFA'1-120, (9:1), (1 OmI), under an inert atmosphere of nitrogen 
compound 81, (0.5g, 0.85m1v1) is added. The mixture was stirred for three hours the 
TFA removed in vacuo, water added and the cloudy white product re-extracted into 
ethyl acetate (2 x 50m1). The ethyl acetate was dried with MgSO 4 and the .product 
absorbed from this solvent onto silica and then purified via wet flash 
chromatography. Elution with ethyl acetate/hexane gave the title compound as an 
oil. (0.38g. 89%); HPLC (Vydac C18,250 x 4.6mm, 5!.tM, A=11 20, B=CH3CN, 
0.1% TFA; lmllmin. 10% B for 2 mins then 10-100% B over 35 mins; X=300nm); 
Rt=3 1.28 mins, 85.59%B; t.l.c. (ethyl acetate/hexane 1:1)Rf 0.46; u m (fi1m); 
3301(NH); 1690 (CO urethane); 1637 (CO amide); X m (MeOH); 269 (c 80000 
dm, 3mor'cnf'); SH(DMSO, 360MHz) 8.40 (111, d, J 8.3911z, fluorenyl NH); 7.85-
7.29 (8H, m, aromatic CH); 6.03 (1H, d, J 8.3611z, fluorenyl CH); 4.39 (1H, t, J 
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5.32Hz, NH); 3.78 (211, s, ester CH 2); 3.24 (41-1, m, CH 20H); 2.95 (21-1, q, J 6.55Hz, - 
CH2CH2NH-); 2.19 (21-1, t, J 7.25Hz, -COCH 2-); 1.27-1.24 (81-1, bs, undecane CH 2 s); 
0.76 (31-1, s, CH 3); SC(DMSO, 90MHz); 173.40 (amide CO); 156.79 (urethane CO); 
145.06, 140.13 (aromatic quaternary); 128.44,127.70,124.84,120.24 (aromatic CM); 
65.98 (ester CH); 63.648 (CH 20H); 54.065 (florenyl CH); 40.97 (-CH2CH2NH-); 
35.38 (-COCH2CH2-); 29.42-25.57 (-CM 2-); 16.54 (CM 3); mlz(FAB) 511 (Mt); 
HRMS 511.32198 C301-142N205 requires: 511.3172 
The synthesis was carried out on 0.25 mM scale using Fmoc-glycine functionalized 
4-alkoxybenzylalcohol resin. All side chains were protected as previously described 
and all residues were coupled using standard double coupling cycles. At the 
completion of the assembly phase, the resin bound peptide was sequentially washed 
with DMF, DCM, ether and dried to give 0.720g of yellow solid. The peptide was 
then cleaved from the resin by treatment with TFAlwater (9:1) for one hour at room 
temperature.. The resin was then removed by filtration and washed with TFA. 
Evaporation of the filtrate and trituration with diethyl ether yielded the crude product 
which was isolated by filtration before being dissolved in acetic acid (10%) and 
lyophilised to yield 111mg of white solid. The peptide was purified by semi-
preparative HPLC (ABI 
Aquapore C18,250 x 9.2mm, 7ini A=H20, B='CH3CN, 0.1% TFA; 5m1/min. 5% B 
for 15 mins then 5-60% B over 40 mins; ? 214nm). The main peak, eluting at 17%B 
was isolated and lyophilised to give 62mg (21%) of the title compound. Analytical 
HPLC (Vydac C18,250 x 4.6mm, 51.xM, A=H 20, BCH3CN, 0.1% TFA; lmllmin. 
5% B for 15 mins then 5-60% B over 40 mins; X 214nm); Rt 27.5 mins; 22.5% B; 
amino acid analysis: Gly 3 2.91, Ala 1 1.09, Phe 1 1.08, Lys, 1.078; m!z (FAB) 6812, 
(MH+) HRMS found 682.33732; C 121-147N70 11 requires: 682.34118. 
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The synthesis was carried out on 0.25mM scale using the Fmoc-Gly functionalised 4-
alkoxyben.zylalcohol resin. All side chains were protected as described previously, 
except for Lysine which was protected with the experimental Tnm group. All 
couplings were carried out using the HOCt coupling agent  and single coupling 
cycles, an extended period of time was given for the lysine compound to dissolve. 
After assembly the resin bound peptide was sequentially washed with DMF, DCM, 
and diethyl ether before being dried to give 672mg of white solid. The Fmoc group 
was removed by sonication of the resin in DMF/piperidine, 4:1 for 20mins. The 
resin was filtered and washed with DFM, DCM, and ether. The resin was then added 
to a round bottomed flask with 4mls of DMF/dioxane( 1:1), phenylacetic acid 
(0.136g. 1mM), HOBt, and sonicated for 2 hours. The resin was washed as above 
and added to a cleavage mixture consisting of 25m1 TFAIH 20 (95:5); and stirred 
under nitrogen for 2 hours. The resin was then removed by filtration and washed 
with TFA. Evaporation of the filtrate and trituration with diethyl ether yielded the 
crude peptide which was isolated by filtration, before being dissolved in aqueous 
acetic acid (15%) and lyophilised to yield 242mg of white solid. The peptide was 
purified using semi-preparative HPLC (Aquapore C18, 250 x 10mm, 10.tM, A=H 20, 
B=CH3CN, 0.1% TFA; 5m1/min. 10% B for 2 mins then 10-90% B over 30 mins. 
A=214nm); Rt 15.22mins; 47%B. The appropriate resultant fractions were combined 
and lyophilised to yield the title compound 102mg. Analytical HPLC (Vydac C18, 
250 x 4.6mm, 5pM, A=1120, B'CH3CN, 0.1% TFA; lmllmin. 10% B for 2 mins 
then 10-90% B over 30 mins; X 214nm); Rt=24mins; amino acid analysis City 3 2.95, 
Ala 1 1.047, Leu 1 0.81, Phe 1 0.938, Lys 1 1.021, mlz (FAB) 944 (MH); HRMS 
944.43527; C43H62N9015 requires:944.43654. 
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The synthesis was carried out on 0.25mM scale using the Fmoc-Gly functionalised 4-
alkoxybenzylalcohol resin. All side chains were protected as described previously, 
lysine with the ordinary Boc group. All couplings were carried out using the HOCt 
coupling agent and single coupling cycles. After assembly the resin bound peptide 
was sequentially washed with DMF, DCM, diethyl ether and dried to give 752mg of 
solid. The Fmoc group was removed by sonication of the resin in DMF/piperidine, 
4:1 for 20mins. The resin was filtered and washed with DFM, DCM, and diethyl 
ether. The resin is the added to a round bottomed flask with 4mls of DMF/dioxane 
(1:1), phenylacetic acid (0.136g. 1 mM), HOBt, and sonicated for 2 hours. The resin 
was washed as above and added to a cleavage mixture consisting of 25m1 TFA!H 20 
(95:5); and stirred under nitrogen for 2 hours. The resin was then removed by 
filtration and washed with TFA. Evaporation of the filtrate and trituration with 
diethyl ether yielded the crude peptide which was isolated by filtration, before being 
dissolved in aqueous acetic acid (15%) and lyophilised to yield 286mg of white solid. 
The peptide was purified using semi-preparative HPLC (Aquapore Cl 8, 250 x 
10mm, lOjiM, A=H20, B=CH3CN, 0.1% TFA; 5m1/min. 10% B for 2 mins then 10-
90% B over 30 mins. A.=214nm); the appropriate resultant fractions were combined 
and lyophilised to yield the title compound 110mg. Analytical HPLC (Vydac Cl 8, 
250 x 4.6mm, 5PM, A=H20, B=CH3CN, 0.1% TFA; imI/min. 10% B for 2 mins 
then 10-90% B over 30 mins; % 214nm); Rt24mins; amino acid analysis Gly 3 2.97, 
Ala1 1.12, Leu 1 0.86, Ph; 0.92, Lys 1 1.04, mlz(FAB) 768 (MH+); HRMS 
767.41470; C 38H55N809 requires: 767.40920 
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The synthesis was carried out on a 0.25mM scale using the Fmoc-Gly fünctionalised 
4-alkoxybenzylalcohol resin. All side chains were protected as previously described 
except Lys63 which was protected using the Trim group. Most amino acids were 
coupled using standard coupling cycles for the 1-JOCt coupling agent. The exceptions 
include, Asn, Gln and Arg, where the initial time period was extended to allow for 
reduced solubility and G1n41 to 1le36 where extended coupling times were used. His 
was also treble coupled as the HOBt ester. 
After the assembly stage the resin was sequentially washed with DMF, DCM, diethyl 
ether and dried to give 1.521g of yellow solid. 
Tbflnoc/Carbon7 purification. 
The resin (200mg) was taken and sonicated in piperidine/DMF 1:4 for twenty 
minutes and subsequently washed with DMF, DCM and diethyl ether. The resin 
bound peptide was then added to a suspension of TbfinocCl (15mg, 0.03mM) and 
DIEA (6jil, 0.03mM) in DCM (5ml), covered in aluminium foil and sonicated at 
room temperature for 3 hours. The Thfmoc-peptide-resin was separated by filtration 
and washed thoroughly with DCM and ether. The dried Tbfmoc-peptide-resin was 
cleaved for 4 hours using TFA (lOml), H20 (0.5ml), phenol (0.5g), EDT (1.5m1) and 
thioanisol (0.5m1) under nitrogen and shielded from light. The resin was then 
removed by filtration and washed with TFA. Evaporation of the filtrate and 
trituration with diethyl ether yielded the crude peptide, which was isolated by 
filtration, before being dissolved in aqueous acetic acid (15%) and lyophilised to 
yield 13 ling of crude peptide. A 75mg portion of this Thfmoc-Ub36-76(Tnm)-
peptide was taken and dissolved in 20m1 of 1:1 6M guanidine.HCI / isopropanol, to 
this was added 267mg of PGC and the suspension vortexed and then centrifuged. 
Adsorption of the Thfmoc-protein was monitored by analytical HPLC of the 
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supernatant at 364nm. The PGC was then subjected to the following washing 
protocol with alternate vortexing and centrifugation: 
1)1:1 6M Gu.HC1 / propan-2-ol (40m1) 
2)1:1 6M Gu.HCI / propan-2-ol (40m1) 
3)1:1 6M Gu.HCI / propan-2-ol (40m1) 
4)10% piperidine in 1:1 6M Gu.HCI / propan-2-ol (20m1) 
5)10% piperidine in 1:1 6M Gu.HCI / propan-2-ol (20m1) 
The supernatant from washes 4&5 were combined and neutralised to pH4.5 with 
AcOH and concentrated in vacuo prior to being loaded onto a Sephadex G25 (fine) 
column (10 x 800mm) pre-equilibrated with 30% AcOH. The column was then 
eluted with 30% AcOH for 48hours (monitoring at 226 and 277nm) and collecting 20 
minute fractions. The relevant fractions were combined, diluted with water and 
lyophilised, yielding 30mg of white solid. Further purification by semi-preparative 
HPLC (Aquapore C18,250 x 10mm, lOsM, A=H 20, B=CH3CN, 0.1% TFA; 
5m1/min. 10% B for 2 mins then 10-90% B over 30 mins. X=214nm) and 
lyophilisation gave Ub36-76 (19mg). Analytical HPLC(Vydac Cl 8, 250 x 4.6mm, 
5p.M, A=H20, B=CH3CN, 0.1% TFA; lml/min. 10% B for 2 mins then 10-90% B 
over 30 mins; k 214nm); Rt 18.20mins; 52%B amino acid analysis (40hrs): Asn 4 
4.13, Thr2 1.95, Ser2 1.95, G1u6 6.09, Pr02 1.58, Gly4 4.65, Ala 1 1.18, Va1 1 1.22, lIe3 
2.64, Leu7 7.00, Tyr 1 0.93, Phe, 1.07, His 1 0.727, Lys2 2.025, Ar94 4.00; mlz(FAB) 
4674; HRMS 4676.5503 1; C206H341N62062 requires: 4676.54252 
Thfmoc HPLC purification 
Thfirioc-Ub36-76(Tnm)-peptide (7 1mg) was purified by semi-preparative HPLC 
(Aquapore C18, 250 x 10mm, lO.tM, A=H 20, B=CH3CN, 0.1% TFA; Sml/min. 10% 
B for 5 rains then 10-40% B over 10 mins then 40-90%B over 30mins; A.=214nm; Rt 
24.5; 56%B) lyophilisation gave Ub(Tmn)36-76 (18.5mg). Analytical HPLC (Vydac 
C18, 250 x 4.6mm, 5j.tM, A=H 20, B=CH3CN, 0.1% TFA; imi/min. 10% B for 2 
mins then 10-90% B over 30 mins; X 214nm); Rt 25.8mins; 72%B; amino acid 
analysis (40hrs): Asn4 3.84, Thr2 1.67, Ser2 1.67, 01u6 5.82, Pr02 1.65., G1y4 3.98, 
Ala 1 1.01, Vai 1 1.05, lie3 2.76, Leu7 6.51, Tyr 1 0.80, Phe 1 0.92, His 1 0.63, Lys2 1.74, 
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Ar94 3.43; mlz ( FAB) 5277; HRMS 5277.70047; C 242H367N63070 requires: 
5277.716 19 
Tbfmoc & Trim removal 
Tbfmoc-peptide 13mg was added to 8m1 of 3:1 DMSO/0.2M borate buffer (pH 8.5) 
and shaken vigorously before being sonicated for 30 minutes. Acetic acid was then 
added to adjust the pH to neutral and the solvent concentrated in vacuo. The solvent 
was loaded onto a Sephadex G25 (fine) column (10 x 800mm) pre-equilibrated with 
30% AcOH. The column was eluted with 30% AcOH for 48hours (monitoring at 
226 and 277nm) and 20minute fractions collected. The relevant fractions were 
combined, diluted with water and lyophilised to give Ub36-79 (9mg). Analytical 
HPLC (Vydac C18,250 x 4.6mm, 5p.M, A=H 20, B=CH3CN, 0.1% TFA; lml/min. 
10% B for 2 mins then 10-90% B over 30 mins; X 214nm); Rt 18.2mins; 52%B; 
amino acid analysis (40hrs): Asn 4 4.08, Thr2 1.90, Ser2 1.85, Glu6 5.85, Pr02 1.54., 
Gly4 4.44, Ala 1 1.09, Val 1 1.10, Ile3 2.50, Leu7 7.00, Tyr 1 0.92, Phe 1 1.05, His 1 0.69, 
Lys2 1.97, Ar94  3.82; mlz(FAB) 4676 HRMS 4676.53916; C 206H341 N62062 
requires:4676.54252 
Z-Glu-OBzl (ig, 2.695mMol) was dissolved in dioxanelDMF 80:20 (SOml) to this 
was added DIC (0.34g. 2.695rnMol), 3-hydroxymethyl-3-methyl-1 ,5-dioxaspiro-5 :5-
undecane (0.5929g. 2.965mMo1) and a catalytic amount of DMAP. The mixture was 
stirred at 5 °C for 1 hour, and then left to stir at room temperature overnight. The 
solvent was then removed in vacuo to leave an oil. The oil was subsequently 
dissolved ethyl acetate and washed with Na 2CO3 (2 x 50m1) and water (2 x 50m1). 
The resultant mixture was dried with MgSO 4 and the solvent removed in vacuo to 
yield the title compound as an oil. Further purification was carried out by wet flash 
chromatography. (0.91g. 57%); [a]D=l 1, c=1.0 in MeOH; (found: C,66.84;H,7.52; 
N,2.40, C31 H39N 1  O requires: C,66.70;H,6.90;N,2.5%);t.l.c. (ethyl acetate/hexane, 
iE! 
1:1); Rf 0.74, o max(Oil) 3344 (NH), 2921 (CH), 1734 (b, CO); SH(DMSO, 250MHz) 
7.32 (1 OH, s, aromatic); 5.15, 5.08 (4H, s,2 x benzyl CH 2); 4.38-4.48 (1H, m, 
czCH);1.37-1.81 (14H, bm, 2 x side chain CH 2s' & cyclohexane ring CH 2s') 0.77 
(3H, s, CH3); 4.12 (2H, s, ester CH 2) 3.57 (4H, s, 2 x dioxane ring CH 2); SC(DMSO, 
50 MHz) 171.16 (CO. 2 x ester); 155.76 (CO, urethane); 134.87, 135.92 9 (aromatic 
quaternary C); 128.26-127.63 (aromatic CH); 97.29 ( aliphatic quaternary); 66.34-
63.58 (13, CH2, ester CH 2, dioxane ring CH 2);52.58 (a, CH);30.19-22.22 
(cyclohexane ring CH 2); 16.23 (CH3);mlz (FAB) 554 (MH), HRMS found 
544.10175 C 31 H39N 1 08  requires 544.10201. 
iI*!,LZIIfl$WJSfiiNUflZIWJ 
Compound 75 (1g. 1.80niM) was added to a round bottomed flask containing ethanol 
(SOml). The flask was cooled in iced water and PdJC catalyst (300mg) added. The 
mixture was then hydrogenated overnight. The PdJC catalyst was filtered off using a 
celite packed sinter funnel (the residue being washed extensively with ethanol; 
200ml). The ethanol is then removed in vacuo to leave a white powder, this was the 
free amine free acid compound, and was used without further purification. To this 
white powder was added Fmoc-succinamide (0.546g, 1.62mM) and K2CO3  (0.49g, 
3.6mM) the mixture was then dissolved in a 1:1 mixture of dioxane/F1 20 and stirred 
overnight. The dioxane was removed in vacuo and the solution washed with diethyl 
ether. The aqueous component is then acidified with potassium hydrogen sulphate 
and the product retrieved by extraction with ethyl acetate. Wet flash chromatography 
was used as a final purification and yields the title product as a white solid. (0.51 g, 
52%); Mpt 174-178°C; [aD]+l  1 c1.0 in MeOH; (found: C,66.8l;H,7.20;N,2.38; 
requires: C,67.39;H,6.88;N,2.50; t.l.c.(ethyl acetate /hexane 7:1) Rf= 0.40; 
u(nujol) 3342 (b, NIIJCOOH) 1733 (b, CO);X M (MeOH) 265nm (c 23000 dm3 
mol' cmj, 290 (5700) 300 (7000); SH(DMSO, 360MHz) 7.92-7.29 (aromatic CH); 
4.33-4.18 (2H, m, Fmoc CH 2); 4.04-3.92 (1H, m, Fmoc CH); 3.93 (2H, s, ester CH 2); 
3.26 (4H, s, dioxane ring CH 2); 2.13-1.29 (14H, bm, 13 CH 2's & ring CH2's); 0.78 
'(It 
(C1-13);8C(DMSO, 90MHz) 173.44, 172.22 (CO, acid, ester); 156.16 (CO, urethane); 
143.89,140.77 (aromatic quaternary); 127.69-120.16 (aromatic CH); 65.67 (Fmoc 
CH2); 59.93 (2 x CH20H & ester CH 2); 52.99 ((x CH); 46.71 (Fmoc CH); 30.19, 
26.13 (f3 CH2 's); 14.13 (CH3); mlz (FAB) 552 (MIt), HRMS found 552.25961; 




The synthesis was carried out on a 0.268 mM scale using Fmoc-glycine 
flinctionalised 4-alkoxybenzylalcohol resin, all amino acid side chains were protected 
as previously described, cysteine being protected as the Acm derivative. Amino 
acids were double coupled using standard coupling cycles, except for the last 10 
residues which were allowed to couple for an extended period of time. The N-
terminal Fmoc group was left on at the completion of the assembly phase. The resin 
bound product was washed sequentially with DMF, 1 ,4-dioxan, DCM and diethyl 
ether to give 1.428g of resin bound product. 
Fmoc protected resin bound product (105g) was treated with 20% piperidinelDMF 
(lOmls) in a sonic bath for 15 mins, after which the resin bound product was filtered, 
washed as previously, and dried to give 95mg of resin bound product. The peptide 
was then cleaved from the resin using a cleavage mixture consisting of 250gl EDT, 
250g1 EMS, 250Lil H20, 250mg Phenol and 9mls TFA. The mixture was stirred with 
the resin bound peptide under an atmosphere of nitrogen for 3 Hours. Subsequently 
the resin was removed by filtration and the filtrate concentrated in vacuo to give an 
oil. This oil yielded solid peptide on trituration with diethyl ether. The solid peptide 
was then filtered off, washed with diethyl ether, and dissolved in aqueous acetic acid 
(15%). The aqueous solvent was then removed by lyophilisation to leave 42mg of 
crude product. This impure peptide was then re-dissolved in 30% acetic acid and 
purified by semi-preparative Rp HPLC (ABI, Aquapore Rp300; C18, 250 x 9.2 mm, 
7.tm A=H20, B=CH3CN, 0.1% TFA; 5m1/min, 10%B for 2 mins then 10-90%B over 
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30 mm. X=214nm). The appropriate resultant fractions were combined and 
lyophilised to give a white solid. (20mg); Analytical HPLC (ABI, Aquapore Rp300; 
Cl 8,220 x 4.6 mm, 7pm AH 20, B=CH3CN, 0.1% TFA; lml/min; 10%B for 2 
mins then 10-90%B over 30 mm, X=214nm) Rt=22mins 64.5%B; amino acid 
analysis Asp ] 1.28, Ser i 1.20, 01u4 4.76, Pr02 2.21, G1y3 3.38, Ala2 2.36, Cys2 
0.3(Acm), Va1 2 2.08, Met2 0.8, 11e3 3.29, Tyr2 1.13, Phe3 3.37, Lys2 2.25, Arg 1 0.97; 
mlz (FAB) 3754 (MH+), HRMS found 3754.81128; C 173 H257N42044S4 requires 
3754.80472. 
Removal of the Acm cysteine protecting group 
1) Mercury (II) Acetate (HgAc) method. 
The peptide 92 (15mg, 3.99 x 10mM) was dissolved in the minimum volume of 
30% aqueous acetic acid, to this was added 100mg of Hg(Ac) and the mixture stirred 
for one hour at room temperature. 0.8mls of —mercaptoethanol was then added and 
the mixture stirred for an additional hour. The precipitated mercury salt was 
removed by filtering through celite and the filtrate examined under Analytical HPLC 
(ABI, Aquapore Rp300; C18, 250 x 4.6 mm, 7pm A=H 20, B=CH3CN, 0.1% TFA; 
lmllmin; 10%B for 2 mins then 10-90%B over 30 mm. ?.=214nm). Two peaks were 
present, one corresponding to the unreacted protected peptide (Rt=22mins), (Mass 
3754), and the other (Rt=2 1 .Smins) to a mono Acm protected derivative (Mass 
3680). The mono protected peptide (3mg, 8.152 x 10 4mM), after isolation via semi-
preparative HPLC, was stirred with Hg(Ac) (100mg, 0.3 1mM) for 1 8hrs: (3-
mercaptoethanol (0.8mls, 11.40mM) was then added, the residue removed by 
filtration and the filtrate examined under analytical HPLC. There was no change in 
retention time, the peak was isolated by semi-preparative HPLC and lyophilised 
(I mg). Quantitative Ellman's 3  test suggested only one Acm had been removed i.e. no 
change; mlz (FAB) 3680, HRMS found 3683.76431; C 170H252N41 043 requires 
3683 .76773. 
In a final effort to remove the Acm protecting groups using the Hg(Ac) method, 
peptide 92 (20mg, 5.3 x 1 0 3mM) was dissolved in 1 Omls of 1:1 acetic acid, Hg(Ac) 
(110mg, 0.35 mM) added, and the mixture placed in a sonic bath at 40°C overnight. 
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13—mercaptoethanol (I ml, 14mM) was added and the mixture stirred for two hours 
before being filtered through celite. The filtrate was diluted and freeze dried. 
Analytical I-IPLC showed a number of peaks, the major constituents were separated 
as best as possible by semi-preparative HPLC and sent for mass spectroscopy. This 
yielded poor results and indicated that the peptide had broken up during sonication. 
The pattern of peaks around a fragment weighing 2812 and giving a qualitatively 
positive Eliman's test suggests that one of the Acm groups remains attached even 
though the peptide has broken up. This suggests removal of both Acm's using this 
method is unlikely to be successful. 
Removal of Acm using silver trifilate. 
Peptide 92 (8mg, 2xlW 3mM) was added to a round bottomed flask containing 5mls 
of TFA and stirred with 20 equivalents of silver trifluromethanesulphonate (11mg 
0.0426mM) at 0°C in the dark for 2 hours. The TFA was removed in vacuo and the 
residue triturated with cold ether to precipitate the silver salt of the peptide. This was 
taken up in 50% AcOH (4mls) and treated with 100 equivalents of DTT (3 ling, 
0.2mM) overnight in the dark at room temperature. After centrifugation (4500 revs 
for 30mins) the supernatant was decanted from the brown pellet and diluted with 
water to 1 Oral volume. The residual brown pellet was washed with 50% AcOH (2ml) 
and the supernatant again collected after centrifugation of the solution. This was 
diluted with water to 5mls volume and combined with the 1 Oml solution. The 
peptide was isolated by semi-preparative HPLC (ABI, Aquapore Rp300; C18, 250 x 
9.2 mm, 7p.sm A=H20, B=CH3CN, 0.1% TFA; 5m1/min, lO%B for 2 mins then 10-
90%B over 30 mm, %=214nm). The appropriate fractions were lyophilised to yield 
3mg of product. Ellman's test proved negative; m/z 3754; therefore Acm groups 
have not been removed, hence procedure abandoned. 
it 1:1 
Gp-I20 Peptide (93) 
Gly-Glu-Phe-Phe-Tyr-Cys(tBuS)-Val-Cys(tBuS)-Arg-Ile-Lys-Gln-Phe-Ile-Asn-Met-
Trp-Gln-Glu-Val-Gly-Lys-Ala-Met-Tyr-Ala-Pro-Pro-Ile-Ser-Gly 
The synthesis was carried out on a 0.25 mM scale using Fmoc-Glycine 
functionalised 4-alkoxybenzylalcohol resin, all amino acid side chains were protected 
as previously described, cysteine being protected as the tBuS derivative. Amino 
acids were double coupled using standard coupling cycles, except for the last 10 
residues which were allowed to couple for an extended period of time. The synthesis 
was interrupted after the arginine residue and two thirds of the resin removed and 
stored. The synthesis was continued on the remaining third incorporating tBuS 
protected cysteines. The N-terminal Fmoc group was left on at the completion of the 
assembly phase, after which the resin bound product was washed sequentially with 
DMF, 1,4-dioxin, DCM and diethyl ether to give 0.750g of resin bound product. 
Fmoc protected resin bound product (100mg), was treated with 20% piperidine/DMF 
(1 Omls) in a sonic bath for 15 mins, after which the resin bound product was filtered 
off, washed as previously, and dried to give 91mg of resin bound product. The 
peptide was cleaved from the resin using a cleavage mixture consisting of 250js1 
EDT, 250jil EMS, 250pJ H20, 250mg Phenol and 9mls TFA. The mixture was 
stirred with the resin bound peptide under an atmosphere of nitrogen for 3 hours. 
The resin was removed by filtration and the filtrate concentrated in vacuo to give an 
oil. This oil yielded solid peptide on trituration with diethyl ether. The solid peptide 
was then filtered off, washed with diethyl ether, and dissolved in aqueous acetic acid 
(15%). The aqueous solvent was then removed by lyophilisation to leave 54mg of 
crude product. The crude product was added to a vial containing 45mls of a mixture 
composed of 95% trifluroethanol and 5% H20. This mixture was placed in a sonic 
bath for 40mins, 1801.d of tributyiphosphine was then added and sonication continued 
for a further hour. The solvent was removed in vacuo and the peptide triturated out 
of solution by the addition of an excess of diethyl ether, filtered and re-dissolved in 
15% acetic acid before being lyophilised. The peptide was then re-dissolved in 50% 
acetic acid and purified by semi-preparative Rp HPLC (this proved very difficult due 
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to constant crashing out of peptide on the guard column) (ABI, Aquapore Rp300; 
Cl 8,250 x 9.2 mm, 7jim A=H20, B=CH3 CN, 0.1% TFA; 5m1/min. 10-90%B over 
30 mm, X=214nm). The appropriate resultant fractions were lyophilised to give a 
white solid. (2mg); positive Eliman's test; analytical HPLC (ABI, Aquapore Rp300; 
C18, 110 x 4.6 mm, 7Mm A='H20, B=CH3CN, 0.1% TFA; lml/min; 10%B for 2mins 
then 10-90%B over 30 min, X=214nm) Rt20mins, 62%B; amino acid analysis Asp 1 
1.31, Ser 1 1.18, G1u4 4.66, Pr0 2 2.24, G1y3 3.38, Ala2 2.37, Cys2 1.57, Va12 2.06, Met2 
1.84, lIe3 3.19, Tyr2 1.63, Phe3 3.36, Lys2 2.3 1, Arg 1 1.07; mlz (FAB) 3612 (MH+), 
FIRMS found 3612.72640, C 1 67H246N40042 S4 requires 3612.72584. 
Oxidation of peptide (93) 
Crude peptide 93 (tBuS removed), (20mg, 5.6 x 10 3mM), was added to 25mls of 5% 
acetic acid, the pH adjusted to 3.5 with NH 4CO3 , 20% by volume of DMSO added 
and the mixture left to stir overnight. The volume was doubled by adding 50% acetic 
acid and the product purified by semi-preparative RP-HPLC (ABI, Aquapore Rp300; 
C18, 250 x 9.2 nun, 7sm A=H20, B=CH3CN, 0.1% TFA; 5m1/min; 10%B for 2mins 
then 10-90%B over 30 min,X=214nm). (This proved very difficult due to constant 
crashing out of the product on the guard column). Appropriate fractions were 
combined and lyophilised to give a white smear (0.2mg); positive Ellman's test: 
oxidation not successful. 
Gly-Glu-Phe-Phe-Tyr-Cys(tBuS)-Pro-(D)Val-Cys(tBuS)-Arg-Ile-Lys-Gln-Phe-I le-
Asn-Met-Trp-Gln-Glu-Val-Gly-Lys-Ala-Met-Tyr-Ala-Pro-Pro-Ile-Ser-Gly 
The synthesis was carried out on the 2/3rds of resin which had been removed during 
the assembly of peptide 93. The synthesis was carried out in exactly the same 
manner as for peptide 93 only the Proline and (D)Valine residues were introduced. 
The N-terminal Fmoc group was left on at the completion of the assembly phase, 
after which the resin bound product was washed sequentially with DMF, 1,4-dioxin, 
DCM and ether to give 1.11 2g of resin bound product. 
I'll] 
100mg of Fmoc protected, resin bound product was treated with 20% 
piperidine/DMF (1 OmIs) in a sonic bath for 15 mins, before the resin bound product 
was filtered off, washed as previously, and dried to give 93mg of resin bound 
product. The peptide was cleaved from the resin using a cleavage mixture consisting 
of 250jsl EDT, 250 j.tI EMS, 250js1 H 20, 250mg Phenol and 9mls TFA. The mixture 
was stirred with the resin bound peptide under an atmosphere of nitrogen for 3 hours. 
The resin was removed by filtration and the filtrate concentrated in vacuo to give an 
oil. This oil yielded solid peptide on trituration with diethyl ether. The solid peptide 
was then filtered off, washed with diethyl ether, and dissolved in aqueous acetic acid 
(15%). The aqueous solution was then removed by lyophilisation to leave 57mg of 
crude product. The crude product was added to a vial containing 50mls of a mixture 
composed of 95% trifluroethanol and 5% H20. This mixture was placed in a sonic 
bath for 40mins, 1 8Ojsl of tributylphosphine was then added and sonication continued 
for a further hour. The solvent was then removed in vacuo and the peptide triturated 
out of solution by the addition of an excess of diethyl ether, filtered, and re-dissolved 
in 15% acetic acid before being lyophilised. The peptide was then re-dissolved in 
50% acetic acid and purified by semi-preparative Rp HPLC (this proved very 
difficult due to constant crashing out of peptide on the guard column) (ABI, 
Aquapore Rp300; C18,250 x 9.2 mm, 7Mm A=H 20, B=CH3CN, 0.1% TFA; 
SmI/min; 10% B for 2mins then 10-90%B over 30 mm, X=214nm). The appropriate 
resultant fractions were combined and lyophilised to give a white solid. (3mg); 
positive ElIman's test; Analytical HPLC (ABI, Aquapore Rp300; C18, 110 x 4.6 
mm, 7Mm A=H20, B=CH3CN, 0.1% TFA; imi/min, 10% B for 2mins then 10-90%B 
over 30 min, X=214nm) Rtl7mins, 55% B; amino acid analysis Asp ] 1. 11, Ser f 
0.88, G1u4 4.52, Pr02 3.80, G1y3 3.23, Ala2 2.24, Cys2 1.32, Va12 2.06, Met2 1.81, lIe3 
3.3 0, Tyr2 1.65, Phe3 3.13, Lys2 2.28, Mg 1  1.18; mlz(FAB) 3711 (MH+), HRMS 
found 3710.78721, C 172H254N41043 S4 requires 3710.78657. 
Oxidation of peptide (94) 
Peptide 94 crude (tBuS removed) (13mg, 3.5 x 104mM) was added to 20m1 of 5% 
aqueous acetic acid and the pH adjusted to 4 with ammonium acetate. DMSO 5m1 
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was then added and the mixture left to stir overnight. The mixture was then diluted 
to double its volume with 50% aqueous acetic acid and the product purified via semi-
preparative RP-HPLC (ABI, Aquapore Rp300; C18,250 x 9.2 mm, 7j.tm A=H 20, 
B=CH3CN, 0.1% TFA; 5m1/min. 10-90%B over 30 mm. X=214nm). (This proved 
very difficult due to constant crashing out of the product on the guard column.) 
Appropriate fractions were combined and lyophilised to give a white powder. (I mg); 
negative Eliman's testAnalytical HPLC (ABI, Aquapore Rp300; C18,250 x 4.6 
mm, 7pm A=H20, B=CH3CN, 0.1% TFA; lml/min; 10-30%B over 10 mm, 30-50% 
over 35 mins X=214nm) Rt19mins, 43%B; mlz (FAB) 3740.1 (MH+), HRMS 
found 3740.77116, C 172H252N41 045 S4 requires 3740.77078. (Mass spec suggests that 
unfortunately the methionine residues have been oxidised as well as the disulfide. 
Several attempts were made to selectively oxidise the disulphide without the 
methionine but these proved unsuccessful). 
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